var title_f10_26_10656="Ultrasound normal median nerve";
var content_f10_26_10656=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1104px;\">",
"  <div class=\"videoplayer\" h264=\"./images/NEURO/71933/US_norm_med_nerve_conv.mp4?title=Ultrasound+normal+median+nerve\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Ultrasound normal median nerve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a real-time axial image of the normal median nerve (arrow), initially at the distal wrist crease. The probe is then slowly moved proximally, in the axial plane, to the mid forearm. Note that the median nerve is initially somewhat speckled but that as the probe moves proximally, the nerve acquires the more classic honeycomb appearance with hypoechoic rounded fascicles surrounded by hyperechoic fibrous tissue. The nerve wraps around and dives deep to the flexor digitorum sublimis muscle and superficial to the flexor digitorum profundus muscle; note the shape change of the nerve from oval to round to triangular to cuboidal as the probe moves up the forearm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Francis O Walker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_26_10656=[""].join("\n");
var outline_f10_26_10656=null;
var title_f10_26_10657="Omoconazole: International drug information";
var content_f10_26_10657=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Omoconazole: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4304018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Afongan (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1979807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Omoconazole Nitrate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Imidazole Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of topical fungal skin infections or vaginal candidiasis",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Topical: Apply once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Vaginal: 1 suppository/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Cream: 1% (15 g, 30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Suppository, vaginal: 300 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10447 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-37992F4EF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_26_10657=[""].join("\n");
var outline_f10_26_10657=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4304018\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979807\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979809\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979812\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979808\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821060\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979811\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10447\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10447|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_26_10658="Rates of IPD after PCV7";
var content_f10_26_10658=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Changes in invasive pneumococcal disease incidence in the era of the conjugate vaccine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 672px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Changes in invasive pneumococcal disease (IPD) incidence by serotype group among children aged &lt;5 years (A) and adults aged &ge;65 years (B), 1998 to 2007.",
"    <div class=\"footnotes\">",
"     * Seven-valent pneumococcal conjugate vaccine (PCV7) was introduced in the United States for routine use among young children and infants in the second half of 2000.",
"    </div>",
"    <div class=\"reference\">",
"     From: Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32. By permission of the Infectious Diseases Society of America. Copyright &copy; 2013 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_26_10658=[""].join("\n");
var outline_f10_26_10658=null;
var title_f10_26_10659="Ketoconazole (topical): Pediatric drug information";
var content_f10_26_10659=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ketoconazole (topical): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38500?source=see_link\">",
"    see \"Ketoconazole (topical): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/51/34612?source=see_link\">",
"    see \"Ketoconazole (topical): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8120613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Extina&reg;;",
"     </li>",
"     <li>",
"      Nizoral&reg;;",
"     </li>",
"     <li>",
"      Nizoral&reg; A-D [OTC];",
"     </li>",
"     <li>",
"      Xolegel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8120614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ketoderm&reg;;",
"     </li>",
"     <li>",
"      Xolegel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10501682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10503607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38500?source=see_link\">",
"      see \"Ketoconazole (topical): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: Shampoo (ketoconazole 2%): Apply to damp skin, lather, leave on 5 minutes, and rinse (one application should be sufficient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Shampoo (ketoconazole 1%): Shampoo twice weekly (at least 3 days should elapse between each shampoo) for up to 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Topical: Apply once daily to twice daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8120805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, foam, topical: 2% (50 g, 100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extina&reg;: 2% (50 g, 100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: 2% (15 g, 30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xolegel&reg;: 2% (15 g [DSC], 45 g) [contains dehydrated ethanol 34%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo, topical: 2% (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nizoral&reg;: 2% (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nizoral&reg; A-D: 1% (120 mL, 210 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8120615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Aerosol, cream, shampoo",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10503608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Shampoo:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     1%: Apply to wet hair and massage over entire scalp for 1 minute; rinse hair thoroughly and reapply shampoo for 3 minutes; rinse",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     2%: Apply to damp skin, covering affected area and a wide margin surrounding the area; lather; leave on 5 minutes; rinse",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical: Apply a sufficient amount and rub gently into the affected and surrounding area. For external use only. Avoid exposure to flame or smoking immediately following application of gel or foam.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10503604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Used topically for treatment of tinea corporis, tinea cruris, tinea versicolor, cutaneous candidiasis, and seborrheic dermatitis (FDA approved in adults); shampoo is used for dandruff (1% shampoo: FDA approved in ages &ge;12 years and adults), seborrheic dermatitis (foam: FDA approved in ages &ge;12 years and adults), and tinea versicolor (shampoo: FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8120604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Nizoral&reg; may be confused with Nasarel, Neoral&reg;, Nitrol&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8120675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Topical cream/gel:",
"     </b>",
"     Acne, allergic reaction, contact dermatitis (possibly related to sulfites or propylene glycol), discharge, dizziness, dryness, erythema, facial swelling, headache, impetigo, keratoconjunctivitis sicca, local burning, nail discoloration, ocular irritation/swelling, pain, paresthesia, pruritus, pustules, pyogenic granuloma, severe irritation, stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Topical foam:",
"     </b>",
"     Application site burning, application site reaction, contact sensitization, dryness, erythema, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo:",
"     </b>",
"     Abnormal hair texture, alopecia, anaphylaxis, angioedema, application site reaction, burning sensation, contact dermatitis, dry skin, hair discoloration, hair loss increased, hypersensitivity, irritation, itching, oiliness/dryness of hair, pruritus, rash, scalp pustules, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10501683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ketoconazole or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10501725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Foam contains alcohol and propane/butane; do not expose to open flame or smoking during or immediately after application",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10501724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity reactions (including rare cases of anaphylaxis) have been reported.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8120700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8120659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8120660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were noted in animal reproduction studies with oral ketoconazole.  Ketoconazole is not detectable in the plasma following chronic use of the shampoo.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10503606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alters the permeability of the cell wall; inhibits fungal biosynthesis of triglycerides and phospholipids; inhibits several fungal enzymes that results in a build-up of toxic concentrations of hydrogen peroxide",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10501726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/51/34612?source=see_link\">",
"      see \"Ketoconazole (topical): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cream is for topical application to the skin only; avoid contact with the eye",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16005 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-FB51BAF4EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_26_10659=[""].join("\n");
var outline_f10_26_10659=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120613\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120614\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501682\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503607\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120805\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120615\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503608\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503604\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120604\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120675\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501683\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501725\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501724\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299555\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120700\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120659\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8120660\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10503606\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10501726\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16005\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16005|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/58/28585?source=related_link\">",
"      Ketoconazole (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/30/2533?source=related_link\">",
"      Ketoconazole (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/62/20457?source=related_link\">",
"      Ketoconazole (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/38/38500?source=related_link\">",
"      Ketoconazole (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/51/34612?source=related_link\">",
"      Ketoconazole (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_26_10660="Defibulation 4";
var content_f10_26_10660=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Defibulation (reversal of female genital infibulation)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Step 4: View of the introitus and urethra after incising coapted labia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_26_10660=[""].join("\n");
var outline_f10_26_10660=null;
var title_f10_26_10661="Butalbital compound and codeine: Patient drug information";
var content_f10_26_10661=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Butalbital compound and codeine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/46/28392?source=see_link\">",
"     see \"Butalbital compound and codeine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F143529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ascomp&reg; with Codeine;",
"     </li>",
"     <li>",
"      Fiorinal&reg; with Codeine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F143530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fiorinal&reg;-C 1/2;",
"     </li>",
"     <li>",
"      Fiorinal&reg;-C 1/4;",
"     </li>",
"     <li>",
"      Tecnal C 1/2;",
"     </li>",
"     <li>",
"      Tecnal C 1/4",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10011593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat tension headaches.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to butalbital, aspirin, caffeine, codeine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703363",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bleeding problems, nose polyps, porphyria, or ulcer disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ringing in ears.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3927405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug with other strong pain drugs or if you are using a pain patch without talking to your doctor first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698544",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a diary of your headaches.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696548",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis. Do not take more than 6 capsules per day.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12530 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-3AAB480B33-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_26_10661=[""].join("\n");
var outline_f10_26_10661=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143529\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F143530\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011593\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011595\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011594\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011599\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011600\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011602\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011597\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011598\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011603\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011604\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/46/28392?source=related_link\">",
"      Butalbital compound and codeine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_26_10662="SLE with pneumonitis PA";
var content_f10_26_10662=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Systemic lupus erythematosus (SLE) with pneumonitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph shows diffuse faint bilateral linear and reticular opacities consistent with thickened interlobular septa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_26_10662=[""].join("\n");
var outline_f10_26_10662=null;
var title_f10_26_10663="Acromioclavicular joint injuries";
var content_f10_26_10663=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acromioclavicular joint injuries",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/26/10663/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/26/10663/contributors\">",
"     Scott M Koehler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/26/10663/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/26/10663/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/26/10663/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/26/10663/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/26/10663/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acromioclavicular (AC) joint is situated at the distal end of the clavicle forming an articulation with the acromion of the scapula (",
"    <a class=\"graphic graphic_figure graphicRef62016 \" href=\"UTD.htm?23/41/24210\">",
"     figure 1",
"    </a>",
"    ). The AC joint complex is strong, but its location makes it vulnerable to injury from direct trauma. Injuries to the AC joint are classified according to the position of the clavicle with respect to the acromion and coracoid. Treatment is based upon the extent of injury. AC joint injuries are sometimes referred to as sprains or a &ldquo;separated&rdquo; shoulder.",
"   </p>",
"   <p>",
"    The evaluation and management of AC injuries will be reviewed here. A general approach to the patient with shoulder pain and discussions of other specific shoulder injuries are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link\">",
"     \"Evaluation of the patient with shoulder complaints\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26630?source=see_link\">",
"     \"Glenohumeral osteoarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41592?source=see_link\">",
"     \"Multidirectional instability of the shoulder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21289?source=see_link\">",
"     \"Rotator cuff tendinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY AND BIOMECHANICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acromioclavicular (AC) joint is supported by ligaments that span its anterior, superior, posterior, and inferior aspects (",
"    <a class=\"graphic graphic_figure graphicRef62016 \" href=\"UTD.htm?23/41/24210\">",
"     figure 1",
"    </a>",
"    ). These ligaments also envelop the distal 1 to 2 cm of the clavicle. In addition to the AC ligaments, the distal clavicle is held in alignment with the acromion by the strong coracoclavicular (CC) ligaments. These ligaments consist of the conoid ligament medially and the trapezoid ligament laterally. The AC joint itself has a cartilaginous disk and synovial membrane.",
"   </p>",
"   <p>",
"    Joint motion is limited but the clavicle can rotate a few degrees, and small amounts of translation and slight angulation are possible. The clavicle and scapula tend to move in unison, and investigators have shown fully preserved shoulder range of motion with fusion of the AC joint [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10663/abstract/1\">",
"     1",
"    </a>",
"    ]. Anatomic drawings of the shoulder are provided (",
"    <a class=\"graphic graphic_figure graphicRef72709 \" href=\"UTD.htm?15/28/15814\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef54102 \" href=\"UTD.htm?27/60/28613\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef69995 \" href=\"UTD.htm?27/6/27748\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    At physiologic loads, the AC ligaments primarily resist anterior and posterior forces while the CC ligaments resist superior and axial forces [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10663/abstract/1\">",
"     1",
"    </a>",
"    ]. The AC ligament also serves as a secondary restraint to superior displacement. These roles change if excessive loading forces cause injury to the AC joint. As the AC ligaments begin to fail, the CC ligaments bear a greater proportion of the load from anterior and posterior forces, increasing the susceptibility of the CC ligaments to injury.",
"   </p>",
"   <p>",
"    The following provide additional support for the AC joint:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The attachments and fascia of the deltoid and trapezius muscles.",
"     </li>",
"     <li>",
"      The coracoacromial ligament, which provides secondary stability to the joint and absorbs some impact during AC joint trauma.",
"     </li>",
"     <li>",
"      The clavicle, which acts as a strut that holds the scapula and shoulder girdle away from the thorax to improve the leverage and position of the glenohumeral joint.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the physiologic loads on the AC joint, forces from the upper extremity are partially transferred through the AC joint. As an example, compressive forces are increased with adduction of the arm. The stout ligamentous complex described above is necessary to withstand these forces.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY, MECHANISM, AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acromioclavicular (AC) joint is involved in 9 to 12 percent of shoulder girdle injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10663/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Incomplete AC joint injuries (type I or II) occur twice as often as more severe injuries (type III to VI) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10663/abstract/2\">",
"     2",
"    </a>",
"    ]. The great majority occurs in men in their 20s, often during contact sports [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10663/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Injury to the AC joint usually occurs from direct trauma to the superior or lateral aspect of the shoulder (acromion) with the arm adducted, such as a direct blow or falling onto the shoulder (",
"    <a class=\"graphic graphic_figure graphicRef60132 \" href=\"UTD.htm?3/51/3890\">",
"     figure 5",
"    </a>",
"    ). Force correlates with injury. Low force typically causes an AC sprain. Progressive increases in force cause AC ligament rupture, and then sprain and rupture of the coracoclavicular (CC) ligaments.",
"   </p>",
"   <p>",
"    Direct trauma to the shoulder can displace the acromion and scapula inferiorly with respect to the clavicle. This displacement increases the load on the AC ligaments, which stretch and then fail, leading to increased loads on the CC ligaments. Surrounding muscles are unable to support the joint during injury by this direct mechanism.",
"   </p>",
"   <p>",
"    Less often, the AC joint is injured by an indirect force, such as a fall onto an outstretched arm or elbow, which drives the humeral head into the acromion and damages the AC joint. Injury can also occur from forceful adduction of the humerus across the chest.",
"   </p>",
"   <p>",
"    The sequential injury pattern of the AC joint stabilizers has led to an injury classification system that reflects the progression. An initial classification system developed in the 1960s described basic injuries (types I-III), and was expanded by Rockwood to include more severe injuries (types IV-VI) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10663/abstract/3\">",
"     3",
"    </a>",
"    ]. This system is widely used and described in the accompanying table (",
"    <a class=\"graphic graphic_table graphicRef69063 \" href=\"UTD.htm?16/52/17227\">",
"     table 1",
"    </a>",
"    ). Each injury type is also described below. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Specific AC injuries'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the classification system, type should be distinguished from grade. Type refers to the specific AC injury pattern, while grade refers to the extent of injury and applies to any ligament. Grade one ligament injuries involve overstretching without disruption; grade two refers to gross tears with weakness, but without complete ligament disruption; and grade three represents complete ligament disruption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It can be difficult to differentiate among the myriad causes of acute shoulder pain. However, the diagnosis of an acute acromioclavicular (AC) joint injury is often straightforward if the patient has a classic mechanism along with swelling, focal tenderness, and possible deformity of the AC joint. A clinical approach to shoulder pain is described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link\">",
"     \"Evaluation of the patient with shoulder complaints\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H3\">",
"     'Epidemiology, mechanism, and classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History and examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should ask about the mechanism of injury, any previous shoulder injuries or procedures, and any associated neurovascular or cervical spine symptoms.",
"   </p>",
"   <p>",
"    The physical examination often provides clues to the extent of injury. The patient with an AC injury generally exhibits tenderness directly over the AC joint, possibly with deformity. A systematic approach to shoulder inspection and palpation helps the clinician to identify the injuries sustained. Palpation should include: the sternoclavicular (SC) joint, the entire length of the clavicle, the AC joint, the acromion, the spine of the scapula, the coracoclavicular (CC) ligaments, the coracoid process, and the humerus. Focal tenderness suggests injury to the involved structure.",
"   </p>",
"   <p>",
"    If injuries are not severe and the diagnosis is in doubt, the clinician can perform passive cross-body adduction of the arm to compress the AC joint (so-called AC compression or crossover test). If the maneuver elicits pain, it helps to confirm the diagnosis of AC joint injury. Complete evaluation of the shoulder joint is described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link\">",
"     \"Evaluation of the patient with shoulder complaints\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A complete distal neurologic and vascular examination of the involved extremity and screening cervical spine examination should be performed in all cases of suspected AC joint injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial radiographic evaluation of a suspected AC injury can be pursued using either of two approaches: a single anterior-posterior (AP) view including both AC joints; or two AP radiographs, one of the involved shoulder and a comparison film of the uninvolved side. To better visualize the AC joint, exposure is decreased compared with standard shoulder radiographs. The patient's arm should be internally rotated when radiographs are obtained, which increases the sensitivity of plain x-rays for detecting type III injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10663/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Specific AC injuries'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If the initial views are limited, either an AP of the glenoid or a Zanca view can be used for a second view. Stress views (ie, x-rays taken with the patient holding weights) are no longer recommended.",
"   </p>",
"   <p>",
"    The Zanca view (AP with a 10 to 15 degree cephalic tilt) of the involved shoulder highlights the AC joint, which is projected above the scapula (",
"    <a class=\"graphic graphic_picture graphicRef72101 \" href=\"UTD.htm?22/45/23251\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82477 \" href=\"UTD.htm?29/3/29759\">",
"     image 1",
"    </a>",
"    ). This allows the entire AC joint to be seen without overlying images. A Zanca view is especially helpful when any of the following are suspected: a type II AC injury, a distal clavicle fracture, or injury to the physis of the distal clavicle in children.",
"   </p>",
"   <p>",
"    The normal width of the AC joint in adults is 1 to 3 mm. Children and adolescents have a slightly wider joint space, while older adults a somewhat narrower space. By the age of 60, the joint space is often less that 1 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10663/abstract/1\">",
"     1",
"    </a>",
"    ]. Although the normal coracoclavicular (CC) distance ranges from 11 to 13 mm, it is the comparison to the opposite CC joint space that is most important. An increase in CC distance of 25 to 50 percent indicates a complete CC ligament disruption [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10663/abstract/3\">",
"     3",
"    </a>",
"    ]. If coracoid tenderness is present, an axillary radiograph is needed to rule out any associated coracoid fracture. The axillary view also helps to confirm anterior-posterior position of the distal clavicle with injury types III-VI. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Specific AC injuries'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The majority of upper extremity surgeons no longer routinely obtain stress views of the shoulder [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10663/abstract/6\">",
"     6",
"    </a>",
"    ]. Stress views are taken while the patient holds, or has attached, five or ten pound weights in each hand. They were used to differentiate between type II and type III injuries. Physical examination and AC joint views are generally adequate to determine the type of injury and appropriate treatment. Due to the added discomfort and radiation, stress views should be reserved for cases in which the physical examination and standard radiographs leave a specific management dilemma unresolved [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10663/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Specific AC injuries",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I acromioclavicular (AC) injuries represent a partial tear of the AC ligaments, and manifest as a tender AC joint that often has mild swelling but no deformity (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef58609 \" href=\"UTD.htm?8/7/8319\">",
"       image 2",
"      </a>",
"      ). The coracoclavicular (CC) ligaments are nontender and the clavicle is typically nontender, with the exception of the distal-most 1 to 2 cm. Active overhead range of motion (ROM) and cross-body ROM are usually limited by pain. If passive cross-body adduction of the arm to compress the AC joint elicits pain, this helps to confirm AC joint injury if the diagnosis is in question.",
"     </li>",
"     <li>",
"      Type II AC injuries represent a complete tear of the AC ligaments and partial injury of the CC ligaments (",
"      <a class=\"graphic graphic_figure graphicRef54080 \" href=\"UTD.htm?13/44/14031\">",
"       figure 6",
"      </a>",
"      ). They typically manifest as a prominent and tender AC joint, often with significant swelling. There is minimal tenderness of the CC ligaments reflecting lack of significant injury. The stable CC ligaments prevent further superior translation of the clavicle, but there may be instability of the distal clavicle in the horizontal plane. Radiographs show partial elevation of the distal clavicle with no or minimal widening of the CC distance (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef67812 \" href=\"UTD.htm?8/17/8479\">",
"       image 3",
"      </a>",
"      ). Although the normal CC distance ranges from 11 to 13 mm, it is the comparison to the opposite CC joint space that is most important. An increase in CC distance of 25 to 50 percent indicates a complete CC ligament disruption [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10663/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Type III AC injuries involve complete disruption of both the AC and CC ligaments (",
"      <a class=\"graphic graphic_figure graphicRef63069 \" href=\"UTD.htm?18/8/18575\">",
"       figure 7",
"      </a>",
"      ). Deformity of the AC joint is clearly visible, although swelling may obscure the degree of injury (",
"      <a class=\"graphic graphic_picture graphicRef82015 \" href=\"UTD.htm?24/1/24592\">",
"       picture 2",
"      </a>",
"      ). There is marked tenderness of the CC ligaments, which helps distinguish type III from type II injuries. There is usually partial to complete reduction of the separation when the patient shrugs their shoulder. Radiographs show an elevated distal clavicle and increased CC distance compared with the uninjured side (normal 11 to 13 mm) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef59846 \" href=\"UTD.htm?37/38/38509\">",
"       image 4",
"      </a>",
"      ). The distal clavicle is positioned above the plane of the top of the acromion.",
"     </li>",
"     <li>",
"      Type IV AC injuries occur with forceful shoulder trauma that causes disruption of the AC and CC ligaments, and displaces the distal clavicle into or through the trapezius. There is usually a palpable posterior fullness or deformity to the shoulder despite significant swelling. There may be tenting of the posterior skin. Sternoclavicular (SC) dislocations occur more often with type IV injuries. An axillary view x-ray of the shoulder confirms the posteriorly displaced distal clavicle (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef80915 \" href=\"UTD.htm?37/44/38607\">",
"       image 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Type V AC injuries represent significant disruption of the AC and CC ligaments, along with disruption of the muscular and fascial attachments of the distal clavicle. The shoulder appears to droop due to the inferior position of the scapula and glenohumeral joint. There is severe superior displacement of the clavicle, which may cause tenting, ischemia, or even disruption of the overlying skin. The clavicle is perched above the muscle and does not reduce when the patient attempts to shrug their shoulder. The clavicle is elevated above the acromion approximately one to three times the width of the clavicle, and the CC distance is increased two to three times the normal range (11 to 13 mm).",
"     </li>",
"     <li>",
"      Type VI AC injuries are rare and involve severe dislocations of the AC joint in which the distal clavicle is forced into the subacromial or subcoracoid position. There is complete disruption of the AC and CC ligaments and muscular supports. Associated injuries are common and reduction is urgently needed to relieve pressure on the neurovascular bundle. An unusual deformity near the AC joint with a large amount of swelling is common with these injuries.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanism of type VI injuries generally involves a high-energy collision or direct blow to the shoulder. Examples include skateboard or snowboard accidents involving a collision with a fixed object such as a rail or a tree, motor vehicle collisions, and altercations such as with a baseball bat striking the distal clavicle.",
"   </p>",
"   <p>",
"    Multiple trauma may be present, including possible spine and thoracic injuries. A basic trauma assessment should be performed and appropriate management instituted. Thereafter, a careful neurologic and vascular examination is mandatory, followed by emergent reduction should a deficit be identified. If no neurovascular deficit is identified, the examination should be repeated frequently until reduction is performed. AP radiographs reveal a markedly abnormal, inferior position of the clavicle. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"     \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     General issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little high quality evidence to determine when surgical management of acromioclavicular (AC) injuries is necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10663/abstract/8\">",
"     8",
"    </a>",
"    ]. Nevertheless, with the exception of type III injuries, the management of AC injuries is well established. Conservative management with minimal intervention yields excellent results for type I and II injuries, and operative reduction is necessary for type IV, V, and VI injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10663/abstract/2\">",
"     2",
"    </a>",
"    ]. The trend over the last several decades for the initial treatment of type III injuries has moved from operative to nonoperative in the majority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10663/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no role for glucocorticoid (steroid) injections in the acute management of these injuries. Injection may be considered for persistent pain after the ligamentous injury has healed, or in the setting of repeated minor injury with no instability but persistent AC joint arthralgia.",
"   </p>",
"   <p>",
"    Rehabilitation consists of basic motion and strengthening exercises for the shoulder. For type II and type III injuries, the risk of reinjury is increased until the ligaments have fully remodeled, which may require 6 to 10 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Type I",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type I injuries are treated initially with rest, ice, and protection, often with a sling. The patient begins range of motion and strengthening exercises as soon as they are tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10663/abstract/9\">",
"     9",
"    </a>",
"    ]. Return to sport or work is limited only by pain. With special protection, nonthrowing athletes can sometimes return to the very game in which they sustained the injury. Most patients return to full activities between three days and two weeks following injury, although throwing and overhead athletes (eg, baseball pitchers, tennis and volleyball players) often require two to three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10663/abstract/6\">",
"     6",
"    </a>",
"    ]. Complete healing and remodeling of the injured ligaments may take four to six weeks. Type I injuries generally heal without deformity and there is no increased risk of reinjury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Type II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type II injuries usually cause greater pain and swelling than type I. In addition to ice and analgesics, initial management often includes three to seven days of immobilization in a sling. Otherwise, management is comparable to that for type I injuries. The patient begins range of motion exercises as soon as they are tolerated, and may return to normal activity once full range of motion and full strength are regained. This often takes two to four weeks. Complete healing of the ligaments generally requires several more weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Type III",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the large majority of type III injuries, initial treatment is nonoperative, consisting of rest, ice, immobilization with a sling, and analgesics [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10663/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. A sling is helpful for two to three weeks, depending on patient symptoms, to aid healing and relieve pain [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10663/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. The patient begins range of motion and strengthening exercises as soon as the pain is tolerable. The intensity of these rehabilitation exercises is increased gradually and as tolerated based primarily on pain.",
"   </p>",
"   <p>",
"    Patients may return to normal activity between six and twelve weeks following injury, depending on the demands of the activity. Athletes may return to competition once full range of motion and strength is regained [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10663/abstract/10\">",
"     10",
"    </a>",
"    ]. High level athletes and workers that place extreme loads on their shoulder should undergo early orthopedic evaluation. Otherwise, orthopedic consultation should be pursued if pain persists beyond 12 weeks, or returns when the patient increases activity.",
"   </p>",
"   <p>",
"    This nonoperative approach to type III AC injuries is supported by a review of 24 studies comparing operative and nonoperative treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10663/abstract/12\">",
"     12",
"    </a>",
"    ]. Studies included in the meta-analysis were of variable quality and included two randomized controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10663/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. This review, which included 1172 patients with type III AC injuries, found no significant difference in functional outcome between the operative and nonoperative groups (88 versus 87 percent satisfactory outcome respectively), but found significantly higher complication rates among surgical patients. Operative care led to a greater need for further surgery (59 versus 6 percent) and a higher rate of infection (6 versus 1 percent). Greater cosmetic deformity was present among conservatively (ie, nonoperatively) treated patients (37 versus 3 percent). A subsequent review with more limited inclusion criteria reached similar conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10663/abstract/11\">",
"     11",
"    </a>",
"    ]. Both reviews are limited by the dearth of high quality studies on management of intermediate type AC injuries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Types IV, V, and VI",
"    </span>",
"    &nbsp;&mdash;&nbsp;These AC joint injuries are the most severe and require orthopedic evaluation. Emergent referral is needed if neurovascular compromise exists. Type IV injuries may be reduced open or closed and then treated conservatively, as a type III injury, although open repair of the deltotrapezial fascia may improve outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10663/abstract/10\">",
"     10",
"    </a>",
"    ]. Type V injuries require open reduction and repair of the deltotrapezial fascia and reconstruction of the CC ligament [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10663/abstract/10\">",
"     10",
"    </a>",
"    ], with two-thirds of patients achieving good or excellent results [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10663/abstract/6\">",
"     6",
"    </a>",
"    ]. Type VI injuries can involve damage of the neurovascular bundle beneath the coracoid and require open reduction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10663/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long term outlook for these patients depends on the degree of injury and the procedure needed to correct the displaced clavicle. If the distal clavicle is easily reduced with a closed procedure, the injury is converted to a type III with a comparable recovery. If a more extensive procedure is needed, recovery requires additional time and likely more intensive rehabilitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/47/7923?source=see_link\">",
"       \"Patient information: Separated shoulder (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?8/49/8977?source=see_link\">",
"       \"Patient information: Shoulder impingement syndrome (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/21/20818?source=see_link\">",
"       \"Patient information: Acromioclavicular joint injury (shoulder separation) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The acromioclavicular (AC) joint complex is strong, but its position makes it vulnerable to injury from direct trauma. Injuries are classified based on the position of the clavicle with respect to the acromion and coracoid (",
"      <a class=\"graphic graphic_table graphicRef69063 \" href=\"UTD.htm?16/52/17227\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy and biomechanics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Injury to the AC joint usually occurs from direct trauma to the superior or lateral aspect of the shoulder (acromion) while the arm is adducted, such as a direct blow or falling onto the shoulder. The mechanism and classification of AC injuries are discussed in detail above. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology, mechanism, and classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinician should ask about mechanism, previous shoulder injuries or procedures, and associated neurovascular or cervical spine symptoms. Tenderness is present directly over the AC joint and deformity may exist. A systematic approach to shoulder palpation helps with identification of injuries. If injuries are not severe and the diagnosis is in doubt, passive cross-body adduction of the arm to compress the AC joint can help confirm the diagnosis. A complete distal neurovascular exam of the involved extremity and screening cervical spine examination should be performed in all cases. Each injury type is discussed in greater detail above. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiographic evaluation of a suspected AC injury can be pursued using either of two approaches: a single anterior-posterior (AP) view including both AC joints, or two AP radiographs, one of the involved shoulder and a comparison film of the uninvolved side. Stress or weighted views are obsolete. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Radiographs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial management consists of rest, ice, and protection using a sling. Minor injuries (types I and II) are managed nonoperatively. Severe injuries (types IV, V, and VI) should be referred urgently to an orthopedic specialist for operative management. Injuries involving neurologic or vascular deficits require emergent orthopedic referral and intervention. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Operative management of intermediate injuries (type III) does not appear to improve functional outcome when compared with conservative management, and increases the risk of complications. In general, we suggest nonoperative management of type III injuries (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10663/abstract/1\">",
"      Renfree KJ, Wright TW. Anatomy and biomechanics of the acromioclavicular and sternoclavicular joints. Clin Sports Med 2003; 22:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10663/abstract/2\">",
"      Lemos MJ. The evaluation and treatment of the injured acromioclavicular joint in athletes. Am J Sports Med 1998; 26:137.",
"     </a>",
"    </li>",
"    <li>",
"     Rockwood, CA, Williams, G, Young, D. Disorders of the AC join. In: The Shoulder, Volume 1, WB Saunders, Philadelphia 1998. p.483.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10663/abstract/4\">",
"      Pallis M, Cameron KL, Svoboda SJ, Owens BD. Epidemiology of acromioclavicular joint injury in young athletes. Am J Sports Med 2012; 40:2072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10663/abstract/5\">",
"      Vanarthos WJ, Ekman EF, Bohrer SP. Radiographic diagnosis of acromioclavicular joint separation without weight bearing: importance of internal rotation of the arm. AJR Am J Roentgenol 1994; 162:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10663/abstract/6\">",
"      Buss DD, Watts JD. Acromioclavicular injuries in the throwing athlete. Clin Sports Med 2003; 22:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10663/abstract/7\">",
"      Bossart PJ, Joyce SM, Manaster BJ, Packer SM. Lack of efficacy of 'weighted' radiographs in diagnosing acute acromioclavicular separation. Ann Emerg Med 1988; 17:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10663/abstract/8\">",
"      Tamaoki MJ, Belloti JC, Lenza M, et al. Surgical versus conservative interventions for treating acromioclavicular dislocation of the shoulder in adults. Cochrane Database Syst Rev 2010; :CD007429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10663/abstract/9\">",
"      Montellese P, Dancy T. The acromioclavicular joint. Prim Care 2004; 31:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10663/abstract/10\">",
"      Bradley JP, Elkousy H. Decision making: operative versus nonoperative treatment of acromioclavicular joint injuries. Clin Sports Med 2003; 22:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10663/abstract/11\">",
"      Spencer EE Jr. Treatment of grade III acromioclavicular joint injuries: a systematic review. Clin Orthop Relat Res 2007; 455:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10663/abstract/12\">",
"      Phillips AM, Smart C, Groom AF. Acromioclavicular dislocation. Conservative or surgical therapy. Clin Orthop Relat Res 1998; :10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10663/abstract/13\">",
"      Wojtys EM, Nelson G. Conservative treatment of Grade III acromioclavicular dislocations. Clin Orthop Relat Res 1991; :112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10663/abstract/14\">",
"      Press J, Zuckerman JD, Gallagher M, Cuomo F. Treatment of grade III acromioclavicular separations. Operative versus nonoperative management. Bull Hosp Jt Dis 1997; 56:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10663/abstract/15\">",
"      Schlegel TF, Burks RT, Marcus RL, Dunn HK. A prospective evaluation of untreated acute grade III acromioclavicular separations. Am J Sports Med 2001; 29:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10663/abstract/16\">",
"      Bannister GC, Wallace WA, Stableforth PG, Hutson MA. The management of acute acromioclavicular dislocation. A randomised prospective controlled trial. J Bone Joint Surg Br 1989; 71:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10663/abstract/17\">",
"      Larsen E, Bjerg-Nielsen A, Christensen P. Conservative or surgical treatment of acromioclavicular dislocation. A prospective, controlled, randomized study. J Bone Joint Surg Am 1986; 68:552.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 254 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-1.234.2.38-DECD7EA589-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_26_10663=[""].join("\n");
var outline_f10_26_10663=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY AND BIOMECHANICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY, MECHANISM, AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History and examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Specific AC injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      General issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Type I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Type II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Type III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Types IV, V, and VI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/254\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/254|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/3/29759\" title=\"diagnostic image 1\">",
"      Zanca view radiograph of AC joint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/7/8319\" title=\"diagnostic image 2\">",
"      Acromioclavicular injury Type I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/17/8479\" title=\"diagnostic image 3\">",
"      Acromioclavicular injury Type II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/38/38509\" title=\"diagnostic image 4\">",
"      Acromioclavicular injury Type III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/44/38607\" title=\"diagnostic image 5\">",
"      Acromioclavicular injury Type IV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/254|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/41/24210\" title=\"figure 1\">",
"      Normal shoulder ligaments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/28/15814\" title=\"figure 2\">",
"      Basic shoulder anatomy anterior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/60/28613\" title=\"figure 3\">",
"      Basic shoulder anatomy lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/6/27748\" title=\"figure 4\">",
"      Basic shoulder anatomy posterior view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/51/3890\" title=\"figure 5\">",
"      Mechanism of acromioclavicular joint injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/44/14031\" title=\"figure 6\">",
"      Type II AC joint sprain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/8/18575\" title=\"figure 7\">",
"      Type III AC joint sprain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/254|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/45/23251\" title=\"picture 1\">",
"      Zanca radiographic view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/1/24592\" title=\"picture 2\">",
"      Deformity from Type III AC joint injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/254|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/52/17227\" title=\"table 1\">",
"      Acromioclavicular injury grading",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=related_link\">",
"      Evaluation of the patient with shoulder complaints",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26630?source=related_link\">",
"      Glenohumeral osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=related_link\">",
"      Initial evaluation and management of blunt thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41592?source=related_link\">",
"      Multidirectional instability of the shoulder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/21/20818?source=related_link\">",
"      Patient information: Acromioclavicular joint injury (shoulder separation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/47/7923?source=related_link\">",
"      Patient information: Separated shoulder (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/49/8977?source=related_link\">",
"      Patient information: Shoulder impingement syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21289?source=related_link\">",
"      Rotator cuff tendinopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_26_10664="Urethral cancer in men";
var content_f10_26_10664=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Urethral cancer in men",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/26/10664/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/26/10664/contributors\">",
"     Ralph Madeb, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/26/10664/contributors\">",
"     Dragan Golijanin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/26/10664/contributors\">",
"     Edward Messing, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/26/10664/contributors\">",
"     Bridget F Koontz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/26/10664/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/26/10664/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/26/10664/contributors\">",
"     W Robert Lee, MD, MS, MEd",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/26/10664/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/26/10664/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/26/10664/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary urethral cancer is a rare malignancy in men [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Differences in anatomy and etiology lead to important differences in the clinical presentation, diagnosis, and treatment of urethral cancer in men compared to women.",
"   </p>",
"   <p>",
"    Information about the natural history and prognosis of urethral cancer in men is derived from small cases series, and recommendations for treatment are based upon general oncologic principles and extrapolation from other diseases.",
"   </p>",
"   <p>",
"    The diagnosis, evaluation, and treatment of male urethral cancer will be reviewed here. Female urethral cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34357?source=see_link\">",
"     \"Urethral cancer in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urethral cancer is a rare malignancy that accounts for less than 1 percent of urologic cancers diagnosed in the United States and elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/6\">",
"     6",
"    </a>",
"    ]. Urethral cancer has its peak incidence between the ages of 75 and 84 years and is more common in African Americans than in whites [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of urethral cancer is not well understood. Chronic inflammation appears to play an important role, and there is a high incidence of antecedent urethral strictures, trauma, and sexually transmitted diseases, including human papillomavirus infection (HPV) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. No genetic predisposition has been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Chronic inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic inflammation appears to play a role in disease initiation, since many patients with urethral cancer have a history of sexually transmitted disease, urethritis, or urethral stricture [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was illustrated by a study in which men with urethral cancer reported a history of gonococcal urethritis, urethral stricture, or significant trauma in 37, 35, and 7 percent of cases, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/9,12\">",
"     9,12",
"    </a>",
"    ]. In addition, urethral strictures, which may develop following urethral trauma, are most frequently found in the bulbomembranous urethra, which is also the most common urethral segment involved by cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     HPV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A close association exists between infection with oncogenic HPV and squamous cancers of the anogenital tract, including cancers of the penis, cervix, and anus. Although a causative role for HPV in urethral carcinogenesis has not been firmly established, HPV DNA (predominantly the HPV-16 subtype) has been detected in urethral SCCs and the less common TCCs in both men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. This relationship was illustrated by a series in which tumors from 4 of 14 patients (29 percent) harbored detectable HPV [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/13\">",
"     13",
"    </a>",
"    ]. All four were the HPV16 subtype. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=see_link\">",
"     \"Virology of human papillomavirus infections and the link to cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1562?source=see_link&amp;anchor=H3#H3\">",
"     \"Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment\", section on 'HPV infection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31065?source=see_link&amp;anchor=H3#H3\">",
"     \"Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis\", section on 'Role of human papillomavirus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In Taiwan, exposure to arsenic in drinking water has been associated with the development of adenocarcinoma in the bulbomembranous urethra [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ANATOMY AND PATHOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The male urethra extends from the base of the bladder to the external urethral meatus, and averages 21 cm in length. It is customarily divided into prostatic, bulbomembranous, and penile segments [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/16\">",
"     16",
"    </a>",
"    ], or alternatively, into posterior (membranous and prostatic) and anterior (glanular, penile and bulbous) portions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The normal prostatic and bulbomembranous urethral segments are lined with transitional epithelium that is similar to the upper urinary tract. The penile urethra is lined with pseudostratified columnar epithelium, and the meatus is lined with stratified squamous epithelium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Primary tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transitional cell carcinomas (TCCs) and adenocarcinomas arise in the proximal segments of the urethra. Adenocarcinomas are usually closely associated with the periurethral glands of the proximal urethra.",
"   </p>",
"   <p>",
"    Squamous cell carcinomas (SCCs) can arise in the penile (distal) urethra, but SCCs also frequently occur proximally. These proximal SCCs are attributed to squamous metaplasia that occurs in the non-squamous epithelium as a result of chronic inflammation. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Etiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In most reports, SCCs represent the predominant histology, with approximately 75 percent of male urethral cancers being SCCs, while 15 to 20 percent are TCCs, and 5 to 7 percent are adenocarcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/1,4,18\">",
"     1,4,18",
"    </a>",
"    ]. In contrast, in a report of 972 men with urethral cancer identified through the Surveillance, Epidemiology and End Results (SEER) database, TCCs were most common (67 versus 17 and 11 percent, for SCCs and adenocarcinomas, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of urethral cancers arise in the bulbomembranous urethra (59 percent in one series, versus 34 and 7 percent in the penile and prostatic segments, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/1\">",
"     1",
"    </a>",
"    ]). Distal carcinomas tend to infiltrate locally into the corpus spongiosum and corpus cavernosum of the penis, while tumors of the bulbomembranous and prostatic urethra extend into the urogenital diaphragm, prostate, perineum, and scrotal skin [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/1\">",
"     1",
"    </a>",
"    ]. As a result, distal urethral carcinomas are diagnosed earlier, are more amenable to surgical control, and have better prognoses than bulbomembranous and posterior urethral carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rare case reports have documented other primary tumors (eg, melanoma, carcinoid, leiomyosarcomas, lymphomas, small cell carcinomas, paraganglioma) arising in the urethra [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/19-22\">",
"     19-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Lymphatic drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to direct extension into contiguous structures, the major route of spread of urethral cancer is by drainage into regional lymph nodes. The distal urethra drains into superficial and deep inguinal lymph nodes, while the proximal urethra drains into the external iliac, obturator and internal iliac lymph node chains [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Lymphatic metastases tend to follow these same patterns, although variability exists depending upon the exact location of the lesion and whether contiguous structures are involved [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/17,23\">",
"     17,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Between 14 and 30 percent of men with urethral cancers have metastases to the regional lymph nodes at diagnosis, although less than one half of these will have clinically palpable lymphadenopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/1,24,25\">",
"     1,24,25",
"    </a>",
"    ]. Clinical evidence of inguinal lymphadenopathy represents metastatic disease, rather than inflammation, in over 75 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;At diagnosis, roughly 10 percent of patients have distant metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The most frequent sites of involvement are the lungs, liver, and bone. Almost all such patients have large locally extensive primary tumors with regional nodal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PRESENTATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early diagnosis is essential for the successful management of urethral cancer in men. This requires an awareness of the disease in the differential diagnosis in patients presenting with urinary complaints. Because urethral cancer tends to be locally invasive into adjacent soft tissues, many patients have locally advanced disease at diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high index of suspicion is needed for early diagnosis of urethral cancer. Symptoms are often attributed to a benign urethral stricture, which is far more common, may predispose to cancer formation, and sometimes occurs synchronously in men with urethral tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/4\">",
"     4",
"    </a>",
"    ]. Symptoms tend to develop late in the course of the disease and may be insidious in onset. The interval between the onset of symptoms and diagnosis can vary from a few weeks to years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/9,26\">",
"     9,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common symptom is urinary tract obstruction. Other symptoms include hematuria (sometimes with blood dripping from the meatus), dysuria,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a purulent urethral discharge. When hematuria is present, it is more often seen on initiation rather than termination of the urinary stream. Less common symptoms and signs include perineal pain, hematospermia, genital swelling, and priapism [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of a periurethral abscess or fistula in an elderly patient should raise the suspicion for a urethral carcinoma. Tumors arising in the bulbomembranous urethra may present with penile erosion or impotence due to extensive local invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful physical examination including palpation of the entire length of the urethra and regional lymph nodes should be performed in all men who are suspected of having a benign urethral stricture. Moreover, most authorities recommend evaluation for urethral cancer in any man who develops a perineal abscess, unexplained perineal pain, or who has mucosal irregularities, extravasation of contrast medium, or a urethral fistula on retrograde urethrography in the absence of prior instrumentation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/1,4\">",
"     1,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cytologic examination of a voided urine specimen may be helpful in diagnosing some patients. However, the sensitivity of cytology is relatively low [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/1\">",
"     1",
"    </a>",
"    ], and suspicious results require confirmation by transurethral cold cup forceps or needle biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/1,4\">",
"     1,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cystourethroscopy and retrograde urethrography should be routinely performed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/1\">",
"     1",
"    </a>",
"    ]. A biopsy for tissue diagnosis is generally obtained transurethrally at cystoscopy. Friable or ulcerated urethral epithelium is common, although this may not be visualized if there is a tight stricture at or beyond the distal extent of the tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/4\">",
"     4",
"    </a>",
"    ]. Carcinomas arising in the bulbomembranous urethra usually require a bimanual examination under anesthesia to evaluate the extent of local tumor involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/1\">",
"     1",
"    </a>",
"    ]. These procedures can also identify synchronous tumors of the bladder or upper urinary tract [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/4,27\">",
"     4,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Locoregional tumor staging utilizes computed tomography (CT)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    magnetic resonance imaging (MRI) of the abdomen and pelvis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/3,4,25,28\">",
"     3,4,25,28",
"    </a>",
"    ]. The superior soft tissue resolution of MRI allows better delineation of tissue planes and identification of the extent of local invasion. In contrast, CT is better at excluding distant metastases. Care must be taken to include the entire urethra and groin area during imaging.",
"   </p>",
"   <p>",
"    Other routine staging procedures include a chest radiograph and evaluation of renal, hepatic, and hematologic function. Radionuclide bone scanning is only needed if bone metastases are suspected (ie, unexplained pain, elevated alkaline phosphatase), particularly if the presence of such spread would alter management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Staging system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TNM staging system, which is supported by both the American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control (UICC), is used for urethral cancer in males (",
"    <a class=\"graphic graphic_table graphicRef50999 \" href=\"UTD.htm?38/55/39804\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75772 \" href=\"UTD.htm?17/9/17564\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/29\">",
"     29",
"    </a>",
"    ]. Early stage cancers (Ta, Tis, and T1) are typically identified only after histologic study, while more advanced primary tumors are usually recognized on physical examination",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    non-invasive imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The TNM staging system for urethral cancer is also used for transitional cell carcinoma of the prostate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive conclusions comparing treatment strategies cannot be drawn due to the rarity of disease. Hence, general treatment recommendations are based on case reports and small institutional series as well as extrapolation from other diseases.",
"   </p>",
"   <p>",
"    Management is based upon the location of the cancer within the urethra, the extent of disease, and whether or not distant metastases are present. Preventing locoregional recurrence should be the focus of initial management, since this is the most common site of treatment failure.",
"   </p>",
"   <p>",
"    Treatment options are proportional to the extent of local disease. Limited resection or ablation is appropriate for solitary superficial lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/17,30\">",
"     17,30",
"    </a>",
"    ]. More deeply invasive lesions and those with locoregional spread may require more aggressive surgical management [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/1,30\">",
"     1,30",
"    </a>",
"    ], and multimodality therapy should be considered. &nbsp;",
"   </p>",
"   <p>",
"    The primary factors influencing prognosis are the stage, location, and histologic grade of the tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/31\">",
"     31",
"    </a>",
"    ]. Other significant adverse prognostic factors include the presence of metastases in lymph nodes and squamous cell histologic features [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1340264963\">",
"    <span class=\"h2\">",
"     Early stage lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical management is most commonly offered and felt to be the preferred strategy for small non-invasive or minimally invasive urethral cancers. Surgical resection offers excellent local control (83 and 100 percent in two series) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], and long-term disease control, with overall survival reported between 70 to 100 percent at five years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/8,31-33\">",
"     8,31-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Local treatment modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;For superficial, stage Ta, Tis, and T1 (low-grade papillary) solitary lesions (",
"    <a class=\"graphic graphic_table graphicRef50999 \" href=\"UTD.htm?38/55/39804\">",
"     table 1",
"    </a>",
"    ), transurethral resection (TUR) or fulguration is often adequate [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/17,30\">",
"     17,30",
"    </a>",
"    ]. As long as the tumor can be completely resected, its location is unimportant, and even lesions in the bulbomembranous urethra can be successfully treated in this manner [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/18,34\">",
"     18,34",
"    </a>",
"    ]. However, TUR should be used cautiously in men with proximal tumors that are adjacent to the external urethral sphincter, since incontinence may result if the bladder neck is damaged.",
"   </p>",
"   <p>",
"    Laser ablation with the Holmium laser is another effective treatment strategy for early lesions and may lesson the likelihood of posttreatment stricture formation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/35\">",
"     35",
"    </a>",
"    ]. However, a biopsy must be obtained before the laser is used.",
"   </p>",
"   <p>",
"    Mohs micrographic surgery may be an alternative surgical technique for selected patients with distal carcinoma in situ, although the available experience is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=see_link&amp;anchor=H12329803#H12329803\">",
"     \"Treatment of basal cell carcinomas at high risk for recurrence\", section on 'Mohs surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential major complications of local treatment include urethral perforation, fistula formation, and the delayed development of urethral strictures. Urethral perforation and fistulization can be treated with prolonged (eg, 10 days) Foley catheter placement. Retrograde urethrography is necessary before removing the catheter. Urethral strictures following treatment can be successfully managed with endoscopic urethrotomy or periodic urethral dilation. However, tumor recurrence must be ruled out initially.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Partial penectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men with low-stage distal urethral tumors who cannot be managed with TUR, partial penectomy can often provide good disease control while sparing most penile functions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/30,38\">",
"     30,38",
"    </a>",
"    ]. The tumor must be situated such that a 2 cm proximal tumor-free margin can be obtained while preserving sufficient penile length to allow urination in the standing position [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/30\">",
"     30",
"    </a>",
"    ]. Tumor involvement of the proximal urethra is a contraindication to partial penectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/17,30\">",
"     17,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Radical penectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radical penectomy is recommended for patients with stage Ta-T2 penile urethral tumors (",
"    <a class=\"graphic graphic_table graphicRef50999 \" href=\"UTD.htm?38/55/39804\">",
"     table 1",
"    </a>",
"    ) in whom there are inadequate margins for partial penectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/30\">",
"     30",
"    </a>",
"    ]. Radical penectomy may also be necessary for some distal urethral cancers that have extended into the corpora cavernosa. Radical penectomy has similar treatment failure rates to partial penectomy for locally extensive tumors.",
"   </p>",
"   <p>",
"    Radical penectomy cannot be performed on patients with bulbomembranous urethral tumors who have an inadequate length of disease free proximal urethra to create a perineal urethrostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Surgical management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Removal of the scrotum and its contents is indicated only when the overlying skin is involved [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/1\">",
"     1",
"    </a>",
"    ]. Scrotal hematoma, wound infection, and perineal urethrostomy stenosis are specific risks of this procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1340265032\">",
"    <span class=\"h3\">",
"     Non-surgical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy (RT), with or without chemotherapy, is usually reserved for patients who are not candidates for surgery due to comorbidity or who refuse resection. Isolated case reports indicate that RT can be efficacious [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/12,31,32,39,40\">",
"     12,31,32,39,40",
"    </a>",
"    ], but its role compared to surgery is unknown. Although RT has the advantage of preserving the penis and urethra, potential side effects can include urethral stricture and edema [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1340265105\">",
"    <span class=\"h2\">",
"     Locally advanced lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Locally advanced lesions require more aggressive treatment to control the primary tumor and prevent recurrence. In recent years, several case reports describing a multidisciplinary approach have been published. This strategy attempts to maximize local control while minimizing organ dysfunction. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Surgical management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penectomy plus an en bloc resection of the urethra, prostate, and bladder (cystoprostatectomy) are indicated to treat proximal T3 or T4 urethral cancers (",
"    <a class=\"graphic graphic_table graphicRef50999 \" href=\"UTD.htm?38/55/39804\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/1,4,30,41\">",
"     1,4,30,41",
"    </a>",
"    ]. Extending the operation to include resection of the pubic rami and adjacent urogenital diaphragm will allow intact removal of the entire urogenital compartment and may improve the margin of resection and local control, and this may result in a disease-free survival rate of approximately 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/30\">",
"     30",
"    </a>",
"    ]. Wound infection or dehiscence, abscess formation, perineal hernia, and disruption of the sacroiliac joints are possible complications due to the extensive dissection and a large potential space left after pubic resection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/30,41\">",
"     30,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A regional lymphadenectomy that encompasses inguinal and pelvic nodes is recommended for everyone with palpable inguinal lymphadenopathy, because of the high likelihood of nodal involvement and long-term disease-free survival in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/18,31,42\">",
"     18,31,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of \"prophylactic\" inguinal lymphadenectomy in patients with clinically negative lymph nodes is uncertain. Although occult metastases are not infrequent, inguinal lymphadenectomy causes significant morbidity in 30 to 50 percent of patients. Important side effects can include flap necrosis, leg edema, scrotal edema, seroma, or wound infection.",
"   </p>",
"   <p>",
"    Sentinel inguinal lymph node biopsy (SLNB) has been advocated based upon experience with this procedure in men with penile cancer; this is followed by an extended lymph node dissection if a positive lymph node is identified [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/31\">",
"     31",
"    </a>",
"    ]. However, there is a significant incidence of false negative SLNBs in patients with penile cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26840?source=see_link&amp;anchor=H324012657#H324012657\">",
"     \"Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis\", section on 'Dynamic sentinel node biopsy (DSNB)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since the technique of lymph node dissection has improved and is associated with less morbidity and mortality than was originally reported, we suggest that therapeutic lymph node dissection be performed in all patients with high-stage or high-grade (regardless of stage) urethral carcinoma, whether the lymph nodes are clinically positive or negative.",
"   </p>",
"   <p>",
"    Local control with surgical management has improved with earlier diagnosis, improved staging,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    refinements in treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/1,4,8,31\">",
"     1,4,8,31",
"    </a>",
"    ]. In the 1980s, 33 percent of patients were disease-free at a median follow up of 29 months. In contrast, in the 1990s, this had increased to 52 percent at a mean follow-up of 50 months [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/8,31\">",
"     8,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1340265295\">",
"    <span class=\"h3\">",
"     Adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant radiotherapy can be offered to men with locally advanced disease or those with positive margins after resection to reduce likelihood of local recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/33\">",
"     33",
"    </a>",
"    ] and time to progression [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/43\">",
"     43",
"    </a>",
"    ]. Additive morbidity (ie, edema) and normal structures limit the dose of radiation that can be given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1340265302\">",
"    <span class=\"h3\">",
"     Neoadjuvant therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative chemotherapy, RT, or the combination has been used in several reports [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/40,41,44\">",
"     40,41,44",
"    </a>",
"    ], and may aid in downsizing the primary tumor as well as improving local control [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/44\">",
"     44",
"    </a>",
"    ] and disease-free survival [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/40\">",
"     40",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Trimodality therapy, chemoradiation followed by surgical resection, has improved outcomes compared with historical controls in small series. The potential role for this approach was illustrated by a single institution series of 18 men (17 with SCC and one with adenocarcinoma) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/45\">",
"     45",
"    </a>",
"    ]. Most patients had advanced disease, including 10 of 12 assessable patients with T3 or T4 primary tumors (83 percent) (",
"    <a class=\"graphic graphic_table graphicRef50999 \" href=\"UTD.htm?38/55/39804\">",
"     table 1",
"    </a>",
"    ). Six (33 percent) had clinical evidence of regional lymph node involvement. The initial treatment produced a complete response in 15 of 18 (83 percent). Two cycles of chemotherapy (5-FU plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    ) were administered after RT to the primary lesion and regional lymph nodes. The overall five-year disease-specific survival for the series was 60 percent (54 percent with chemoradiotherapy alone and 72 percent when patients who were treated with surgery after a recurrence were included). Another series that included both men and women reported a 72 percent crude local control rate with a median follow-up of 32 months after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1340265441\">",
"    <span class=\"h3\">",
"     Definitive chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;This strategy can be utilized for patients who are not candidates for primary surgery, who have refused surgery, or who have excellent neoadjuvant responses [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/40,45-47\">",
"     40,45-47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1340265456\">",
"    <span class=\"h3\">",
"     Palliative therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive single modality chemotherapy or RT may be useful in palliation, but has generally not been very effective at providing long term local or distant control [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/8,48\">",
"     8,48",
"    </a>",
"    ]. Activity has been observed with the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and 5-FU [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/49\">",
"     49",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/50\">",
"     50",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and cisplatin (MVAC) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following potentially curative treatment for urethral cancer, all men require close follow-up including retrograde urethrography, cystoscopy and urethral cytologic washes to detect any evidence of recurrent disease. Our practice is to repeat these procedures at least every three months for 24 months. The frequency of follow-up is decreased subsequently if the patient remains disease-free. Advanced lesions may require imaging for surveillance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266388244\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for men with carcinoma of the urethra was analyzed in a Surveillance, Epidemiology and End Results (SEER) database series of 2065 patients diagnosed and treated between 1988 and 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10664/abstract/51\">",
"     51",
"    </a>",
"    ]. In this series, approximately 78 percent of patients had urothelial (transitional cell) carcinoma, 12 percent squamous cell carcinoma, and 11 percent other histology. The status of regional lymph nodes was negative, positive, or unknown in 72, 6, and 22 percent of cases, respectively; in 5 percent, metastases were present at presentation.",
"   </p>",
"   <p>",
"    Cancer-specific survival rates at five and 10 years were 68 and 60 percent, respectively. On multivariate analysis, factors associated with an improved prognosis included younger age, the absence of nodal or distant metastases (TNM stage), and lower histologic grade.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diagnosis at an early stage is essential to maximize the chances of cure. Detailed evaluation, including cystourethroscopy and retrograde urethrography, are mandatory in all men with symptoms or signs suggestive of urethral cancer. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Presentation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men with stage Ta, Tis, and T1 (low-grade papillary) solitary lesions (",
"      <a class=\"graphic graphic_table graphicRef50999 \" href=\"UTD.htm?38/55/39804\">",
"       table 1",
"      </a>",
"      ), we recommend local treatment, rather than a more aggressive procedure, to eradicate the tumor (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Transurethral resection (TUR) or fulguration is most commonly used in this setting. Laser ablation or Mohs microsurgery may represent alternatives in carefully selected patients. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Local treatment modalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men with low-stage distal urethral tumors, we recommend partial, rather than radical, penectomy as the primary treatment, provided that a 2 cm proximal tumor-free margin is possible (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Partial penectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men with stage Ta-T2 penile urethral tumors (",
"      <a class=\"graphic graphic_table graphicRef50999 \" href=\"UTD.htm?38/55/39804\">",
"       table 1",
"      </a>",
"      ) in whom there are inadequate margins for partial penectomy, we recommend a radical penectomy with perineal urethrostomy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Radical penectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For men with proximal urethral stage T3 or T4 cancers, a multidisciplinary approach should be considered, as neoadjuvant chemoradiation seems to improve outcomes. Surgical treatment should consist of an en bloc resection of the urethra, prostate, and bladder, along with penectomy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Surgical management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all men with either T3 or T4 cancers or with a high-grade lesion regardless of stage, we suggest performing a therapeutic lymph node dissection, whether the lymph nodes are clinically positive or negative (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). There is inadequate experience to recommend using sentinel lymph node biopsy in patients with urethral cancer. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Surgical management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Fair WR, Chi-Rei Y. Urethral carcinoma in males. In: Current Therapy in Genitourinary Surgery, 2nd, Resnick MI, Kursh BC (Eds), Decker, 1997. p.157.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/2\">",
"      Forman JD, Lichter AS. The role of radiation therapy in the management of carcinoma of the male and female urethra. Urol Clin North Am 1992; 19:383.",
"     </a>",
"    </li>",
"    <li>",
"     Herr HW. Surgery of Penile and Urethral Carcinoma. In: Campbell's Urology, 7th, Walsh PC, Retik AB, Vaughan ED, et al (Eds), WB Saunders, 1998. p.3401.",
"    </li>",
"    <li>",
"     Messing EM. Urethrectomy in men and women. In: Master of Surgery: Urologic Surgery, Fowler JE (Ed), Little, Brown, 1992. p.495.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/5\">",
"      Mostofi FK, Davis CJ Jr, Sesterhenn IA. Carcinoma of the male and female urethra. Urol Clin North Am 1992; 19:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/6\">",
"      Cheon J, Kim CS, Lee ES, et al. Survey of incidence of urological cancer in South Korea: a 15-year summary. Int J Urol 2002; 9:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/7\">",
"      Swartz MA, Porter MP, Lin DW, Weiss NS. Incidence of primary urethral carcinoma in the United States. Urology 2006; 68:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/8\">",
"      Dalbagni G, Zhang ZF, Lacombe L, Herr HW. Male urethral carcinoma: analysis of treatment outcome. Urology 1999; 53:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/9\">",
"      Kaplan GW, Bulkey GJ, Grayhack JT. Carcinoma of the male urethra. J Urol 1967; 98:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/10\">",
"      McMillan A, Pakianathan M, Mao JH, Macintyre CC. Urethral stricture and urethritis in men in Scotland. Genitourin Med 1994; 70:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/11\">",
"      Park S, McAninch JW. Straddle injuries to the bulbar urethra: management and outcomes in 78 patients. J Urol 2004; 171:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/12\">",
"      Raghavaiah NV. Radiotherapy in the treatment of carcinoma of the male urethra. Cancer 1978; 41:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/13\">",
"      Wiener JS, Liu ET, Walther PJ. Oncogenic human papillomavirus type 16 is associated with squamous cell cancer of the male urethra. Cancer Res 1992; 52:5018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/14\">",
"      Wiener JS, Walther PJ. A high association of oncogenic human papillomaviruses with carcinomas of the female urethra: polymerase chain reaction-based analysis of multiple histological types. J Urol 1994; 151:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/15\">",
"      Tsai YS, Yang WH, Tong YC, et al. Experience with primary urethral carcinoma from the blackfoot disease-endemic area of South Taiwan: increased frequency of bulbomembranous adenocarcinoma? Urol Int 2005; 74:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/16\">",
"      Carroll PR, Dixon CM. Surgical anatomy of the male and female urethra. Urol Clin North Am 1992; 19:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/17\">",
"      Krieg R, Hoffman R. Current management of unusual genitourinary cancers. Part 2: Urethral cancer. Oncology (Williston Park) 1999; 13:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/18\">",
"      Hopkins SC, Nag SK, Soloway MS. Primary carcinoma of male urethra. Urology 1984; 23:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/19\">",
"      Rudloff U, Amukele SA, Moldwin R, et al. Small cell carcinoma arising from the proximal urethra. Int J Urol 2004; 11:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/20\">",
"      Masuda A, Tsujii T, Kojima M, et al. Primary mucosa-associated lymphoid tissue (MALT) lymphoma arising from the male urethra. A case report and review of the literature. Pathol Res Pract 2002; 198:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/21\">",
"      Boyle M, Gaffney EF, Thurston A. Paraganglioma of the prostatic urethra. A report of three cases and a review of the literature. Br J Urol 1996; 77:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/22\">",
"      Hofmockel G, D&auml;mmrich J, Manzanilla Garcia H, et al. Primary non-Hodgkin's lymphoma of the male urethra. A case report and review of the literature. Urol Int 1995; 55:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/23\">",
"      Johnson DW, Kessler JF, Ferrigni RG, Anderson JD. Low dose combined chemotherapy/radiotherapy in the management of locally advanced urethral squamous cell carcinoma. J Urol 1989; 141:615.",
"     </a>",
"    </li>",
"    <li>",
"     Applewhite JC, Hall MC, McCullough DL. Urethral Carcinoma. In: Adult and Pediatric Urology, 4th, Gillenwater JY, Grayhack JT, Howards SS, et al (Eds), Lippincott Williams and Wilkins, 2002. p.1791.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/25\">",
"      Vapnek JM, Hricak H, Carroll PR. Recent advances in imaging studies for staging of penile and urethral carcinoma. Urol Clin North Am 1992; 19:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/26\">",
"      Anderson KA, McAninch JW. Primary squamous cell carcinoma of anterior male urethra. Urology 1984; 23:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/27\">",
"      Bretton PR, Herr HW, Whitmore WF Jr, et al. Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra. J Urol 1989; 141:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/28\">",
"      Pavlica P, Barozzi L, Menchi I. Imaging of male urethra. Eur Radiol 2003; 13:1583.",
"     </a>",
"    </li>",
"    <li>",
"     Urethra. In: American Joint Committee on Cancer Staging Manual, 7th, Springer, New York 2010. p.507.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/30\">",
"      Zeidman EJ, Desmond P, Thompson IM. Surgical treatment of carcinoma of the male urethra. Urol Clin North Am 1992; 19:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/31\">",
"      Dinney CP, Johnson DE, Swanson DA, et al. Therapy and prognosis for male anterior urethral carcinoma: an update. Urology 1994; 43:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/32\">",
"      Eng TY, Naguib M, Galang T, Fuller CD. Retrospective study of the treatment of urethral cancer. Am J Clin Oncol 2003; 26:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/33\">",
"      Farrer JH, Lupu AN. Carcinoma of deep male urethra. Urology 1984; 24:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/34\">",
"      Konnak JW. Conservative management of low grade neoplasms of the male urethra: a preliminary report. J Urol 1980; 123:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/35\">",
"      Kourambas J, Delvecchio FC, Preminger GM. Low-power holmium laser for the management of urinary tract calculi, structures, and tumors. J Endourol 2001; 15:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/36\">",
"      Bernstein G, Forgaard DM, Miller JE. Carcinoma in situ of the glans penis and distal urethra. J Dermatol Surg Oncol 1986; 12:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/37\">",
"      Nash PA, Bihrle R, Gleason PE, et al. Mohs' micrographic surgery and distal urethrectomy with immediate urethral reconstruction for glanular carcinoma in situ with significant urethral extension. Urology 1996; 47:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/38\">",
"      Davis JW, Schellhammer PF, Schlossberg SM. Conservative surgical therapy for penile and urethral carcinoma. Urology 1999; 53:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/39\">",
"      Heysek RV, Parsons JT, Drylie DM, Million RR. Carcinoma of the male urethra. J Urol 1985; 134:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/40\">",
"      Gheiler EL, Tefilli MV, Tiguert R, et al. Management of primary urethral cancer. Urology 1998; 52:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/41\">",
"      Klein FA, Whitmore WF Jr, Herr HW, et al. Inferior pubic rami resection with en bloc radical excision for invasive proximal urethral carcinoma. Cancer 1983; 51:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/42\">",
"      Ray B, Canto AR, Whitmore WF Jr. Experience with primary carcinoma of the male urethra. J Urol 1977; 117:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/43\">",
"      Hussein AM, Benedetto P, Sridhar KS. Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas. Cancer 1990; 65:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/44\">",
"      Dalbagni G, Donat SM, Eschw&egrave;ge P, et al. Results of high dose rate brachytherapy, anterior pelvic exenteration and external beam radiotherapy for carcinoma of the female urethra. J Urol 2001; 166:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/45\">",
"      Cohen MS, Triaca V, Billmeyer B, et al. Coordinated chemoradiation therapy with genital preservation for the treatment of primary invasive carcinoma of the male urethra. J Urol 2008; 179:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/46\">",
"      Baskin LS, Turzan C. Carcinoma of male urethra: management of locally advanced disease with combined chemotherapy, radiotherapy, and penile-preserving surgery. Urology 1992; 39:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/47\">",
"      Licht MR, Klein EA, Bukowski R, et al. Combination radiation and chemotherapy for the treatment of squamous cell carcinoma of the male and female urethra. J Urol 1995; 153:1918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/48\">",
"      Dalbagni G, Zhang ZF, Lacombe L, Herr HW. Female urethral carcinoma: an analysis of treatment outcome and a plea for a standardized management strategy. Br J Urol 1998; 82:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/49\">",
"      Catalona WJ. Re: Modified inguinal lymphadenectomy for carcinoma of the penis with preservation of saphenous veins: technique and preliminary results. J Urol 1988; 140:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/50\">",
"      VanderMolen LA, Sheehy PF, Dillman RO. Successful treatment of transitional cell carcinoma of the urethra with chemotherapy. Cancer Invest 2002; 20:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10664/abstract/51\">",
"      Rabbani F. Prognostic factors in male urethral cancer. Cancer 2010.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2953 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-9A4DD99832-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_26_10664=[""].join("\n");
var outline_f10_26_10664=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Chronic inflammation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - HPV infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ANATOMY AND PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Primary tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Lymphatic drainage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PRESENTATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Staging system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1340264963\">",
"      Early stage lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Local treatment modalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Partial penectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Radical penectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1340265032\">",
"      - Non-surgical management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1340265105\">",
"      Locally advanced lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Surgical management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1340265295\">",
"      - Adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1340265302\">",
"      - Neoadjuvant therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1340265441\">",
"      - Definitive chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1340265456\">",
"      - Palliative therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H266388244\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2953\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2953|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/55/39804\" title=\"table 1\">",
"      Urethral CA TNM men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/9/17564\" title=\"table 2\">",
"      TNM stage group urethra",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1562?source=related_link\">",
"      Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26840?source=related_link\">",
"      Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31065?source=related_link\">",
"      Cervical intraepithelial neoplasia: Definition, incidence, and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=related_link\">",
"      Treatment of basal cell carcinomas at high risk for recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/35/34357?source=related_link\">",
"      Urethral cancer in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=related_link\">",
"      Virology of human papillomavirus infections and the link to cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_26_10665="Postnatal diagnosis and management of alloimmune hemolytic disease of the newborn";
var content_f10_26_10665=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Postnatal diagnosis and management of alloimmune hemolytic disease of the newborn",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/26/10665/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/26/10665/contributors\">",
"     Darlene A Calhoun, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/26/10665/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/26/10665/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/26/10665/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/26/10665/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/26/10665/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/26/10665/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alloimmune hemolytic disease of the newborn (HDN) is caused by the destruction of red blood cells (RBCs) of the neonate or fetus by maternal IgG antibodies. These antibodies are produced when fetal erythrocytes, which express an RBC antigen not expressed in the mother, gain access to the maternal circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transfer of maternal antibodies across the placenta depends upon the Fc component of the IgG molecule, which is different in IgA and IgM. As a result, only maternal IgG causes HDN. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7318?source=see_link&amp;anchor=H8608107#H8608107\">",
"     \"Structure of immunoglobulins\", section on 'Antibody fragments'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The postnatal diagnosis and management of alloimmune HDN in the newborn will be reviewed here. The prenatal diagnosis and management of HDN are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3912?source=see_link\">",
"     \"Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=see_link\">",
"     \"Prevention of Rh(D) alloimmunization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32982?source=see_link\">",
"     \"Overview of Rhesus (Rh) alloimmunization in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3513?source=see_link\">",
"     \"Significance of minor red blood cell antibodies during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF HDN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alloimmune HDN primarily involves the major blood groups of Rhesus (Rh), A, B, AB, and O. However, minor blood group incompatibilities (Kell, Duffy, MNS system, and P system) can also result in significant disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Rh hemolytic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals are classified as Rh negative or positive based upon the expression of the major D antigen on the erythrocyte. The original description of alloimmune HDN was due to Rh(D) incompatibility, which is associated with the most severe form of the disease (hydrops fetalis).",
"   </p>",
"   <p>",
"    The frequency of Rh(D)-negative blood types varies with ethnicity. In the United States, about 15 percent of non-Hispanic whites, 7 percent of Hispanics and blacks, and less than 1 percent of Asians are Rh negative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=see_link&amp;anchor=H14#H14\">",
"     \"A primer of red blood cell antigens and antibodies\", section on 'Rh blood group system'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the introduction of antenatal Rh(D) immune globulin prophylaxis in the 1960s, which significantly reduced alloimmune sensitization in pregnant women who are Rh(D) negative, Rh incompatibility remains the most common cause of alloimmune HDN because of the lack of uniform administration of prophylactic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In 1991, the estimated incidence of Rh alloimmune HDN was 10.6 per 10,000 total births in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=see_link\">",
"     \"Prevention of Rh(D) alloimmunization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although Rh(D) incompatibility remains the most frequent cause of Rh HDN, some of the other more than 44 Rh antigens, particularly E and C, have been associated with HDN (",
"    <a class=\"graphic graphic_table graphicRef82434 \" href=\"UTD.htm?12/25/12702\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=see_link&amp;anchor=H14#H14\">",
"     \"A primer of red blood cell antigens and antibodies\", section on 'Rh blood group system'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Maternal sensitization is due to a previous exposure to Rh antigen either through transfusion with Rh-positive RBCs, or pregnancy with an Rh-positive offspring. Thus, in the absence of transfusion, Rh alloimmune HDN generally does not occur in the first pregnancy.",
"   </p>",
"   <p>",
"    In affected pregnancies, in-utero interventions such as intrauterine transfusions and early delivery have reduced the severity of disease in the newborn, resulting in decreased neonatal morbidity and mortality rates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32982?source=see_link\">",
"     \"Overview of Rhesus (Rh) alloimmunization in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the affected neonate, clinical manifestations of Rh alloimmune HDN range from mild, self-limited hemolytic disease to severe life-threatening anemia (eg, hydrops fetalis). Hyperbilirubinemia usually occurs within the first 24 hours of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     ABO hemolytic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Humans have four major blood groups in the ABO system (A, B, AB, O). At about three to six months of age, individuals naturally begin to make A",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    B antibodies to the antigens (found ubiquitously in food and bacteria) they do not possess. As a result, in contrast to Rh disease, ABO alloimmune HDN can occur with the first pregnancy.",
"   </p>",
"   <p>",
"    Although ABO incompatibility occurs in about 15 percent of all pregnancies, it results in neonatal hemolytic disease in only 4 percent of such pregnancies (ie, 0.6 percent of all pregnancies). ABO hemolytic disease is more common and severe in infants of African descent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infants with ABO HDN generally have less severe disease than those with Rh incompatibility. Hydrops fetalis due to ABO alloimmune HDN is rare and clinically significant hemolysis is uncommon as less than 0.1 percent of infants with evidence of hemolysis will require exchange transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. In one prospective study, maternal IgG anti-A and anti-B titers &gt;512 were associated with severe hyperbilirubinemia that required intervention (eg, phototherapy, intravenous immunoglobulin, or exchange transfusion) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Affected infants are usually asymptomatic at birth and have either no or mild anemia. They generally develop hyperbilirubinemia within the first 24 hours of birth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Minor blood groups hemolytic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor blood group antibodies develop in response to exposure to foreign RBC minor group antigens (eg, Kell, MNS blood system, and Duffy, E) from a previous transfusion or pregnancy, or from exposure to bacteria or viruses that express these antigens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3912?source=see_link\">",
"     \"Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical disease associated with alloimmune HDN due to minor blood groups ranges from mild (hyperbilirubinemia) to severe including hydrops fetalis. The variability is in part dependent upon the blood group (",
"    <a class=\"graphic graphic_table graphicRef55421 graphicRef67208 \" href=\"UTD.htm?20/13/20702\">",
"     table 2A-B",
"    </a>",
"    ). In particular, Kell HDN can be severe and may require intrauterine intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3513?source=see_link&amp;anchor=H8#H8\">",
"     \"Significance of minor red blood cell antibodies during pregnancy\", section on 'Kell blood group'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HDN can be diagnosed postnatally, which will be reviewed here, or antenatally, which is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32982?source=see_link\">",
"     \"Overview of Rhesus (Rh) alloimmunization in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3513?source=see_link\">",
"     \"Significance of minor red blood cell antibodies during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The postnatal diagnosis of alloimmune HDN is based upon the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Demonstration of incompatible blood types between the infant and mother. The most common incompatibilities are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Rh(D) positive infant born to an Rh(D) negative mother",
"     </li>",
"     <li>",
"      A or B blood type in an infant born to a mother with group O blood type",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Demonstration of hemolysis &mdash; Peripheral blood smear findings consistent with HDN include decreased number of RBCs, reticulocytosis macrocytosis, and polychromasia. The normal absolute reticulocyte count in cord blood of term infants is 137.3 &plusmn; 33 x",
"      <span class=\"nowrap\">",
"       10(9)/L,",
"      </span>",
"      which corresponds to a reticulocyte fraction of 3.1 &plusmn; 0.75 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/7\">",
"       7",
"      </a>",
"      ]. Microspherocytosis (due to partial membrane loss) is commonly seen in the peripheral smear of infants with ABO alloimmune HDN, but it is generally not seen in infants with Rh disease.",
"     </li>",
"     <li>",
"      Demonstration of antibody-mediated hemolysis by",
"      <strong>",
"       either",
"      </strong>",
"      a positive direct or indirect antiglobulin test (Coombs test).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A positive direct antiglobulin test demonstrates the presence of maternal antibody on the neonate's RBCs. In this test, agglutination of RBCs from the neonate, when suspended with serum that contains antibodies to IgG, indicates the presence of maternal antibody on the RBC cell surface.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A limitation of the direct antiglobulin test is that this may not detect sensitized RBCs in ABO alloimmune HDN because the A and B antigens are less well developed in neonates than in older children and adults. In addition, the antigenic sites are fewer and further apart on neonatal RBCs, making agglutination with the Coombs' reagent more difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the direct antiglobulin test is negative, an elution is performed on the infant's RBCs to free any bound maternal antibodies into the serum, then an indirect antiglobulin test is performed with the eluted serum. In this test, RBCs with a specific antigen, such as Rh(D), A, or B, are incubated with the infant's serum. Antibodies to the specific antigen will adhere to the RBCs. The RBCs are then washed and suspended in serum containing antihuman globulin (Coombs serum). Agglutination of red cells coated with maternal antibody indicates the presence of free maternal antibodies in the neonatal serum [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In infants with suspected ABO hemolytic disease with both a negative direct antiglobulin test, and indirect test of the infant's eluted serum, other causes for hyperbilirubinemia should be sought. Specifically, evaluations for glucose-6-phosphate dehydrogenase deficiency, pyruvate kinase deficiency, and the UGT1A1 promoter associated with Gilbert syndrome should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=see_link\">",
"     \"Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H7\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In infants with Rh alloimmune HDN who have received intrauterine transfusions, the direct antiglobulin test may be negative because the presence of donor Rh-negative RBCs makes agglutination more difficult. In contrast, the indirect test will remain strongly positive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for alloimmune HDN include other causes of neonatal jaundice",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anemia. Alloimmune HDN is differentiated from the following disorders by the presence of a positive direct or indirect antiglobulin test (Coombs). In addition to being in the differential diagnosis of alloimmune HDN, these disorders can occur concomitantly in an infant with alloimmune HDN. The hyperbilirubinemia may be particularly severe in infants with more than one cause of hyperbilirubinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Diagnosis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=see_link\">",
"     \"Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Erythrocyte membrane defects &mdash; The peripheral blood smear and the negative antiglobulin tests distinguish the inherited erythrocyte membrane defects such as hereditary spherocytosis (",
"      <a class=\"graphic graphic_picture graphicRef70611 \" href=\"UTD.htm?27/1/27670\">",
"       picture 1",
"      </a>",
"      ) or elliptocytosis (",
"      <a class=\"graphic graphic_picture graphicRef63129 \" href=\"UTD.htm?9/61/10199\">",
"       picture 2",
"      </a>",
"      ) from alloimmune HDN. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20506?source=see_link\">",
"       \"Hereditary spherocytosis: Clinical features; diagnosis; and treatment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/16/15623?source=see_link\">",
"       \"Hereditary elliptocytosis: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Erythrocyte enzyme defects &mdash; Enzyme assays confirm the diagnosis of erythrocyte enzyme defects such as glucose-6-phosphate dehydrogenase (G6PD) or pyruvate kinase deficiencies. The presence of Heinz bodies on peripheral blood smear is consistent with a diagnosis of G6PD deficiency (",
"      <a class=\"graphic graphic_picture graphicRef73790 \" href=\"UTD.htm?25/28/26054\">",
"       picture 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=see_link\">",
"       \"Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gilbert's syndrome &mdash; Gilbert's syndrome is the most common inherited disorder of bilirubin glucuronidation. It results from a mutation in the promoter region of the UGT1A1 gene causing a reduced production of UGT, which leads to unconjugated hyperbilirubinemia. A normal hematocrit, reticulocyte count, and peripheral blood smear distinguish this disorder from alloimmune HDN. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=see_link&amp;anchor=H11#H11\">",
"       \"Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn\", section on 'Gilbert's syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed previously, clinical manifestations of alloimmune HDN range from mild, self-limited hemolytic disease (eg, hyperbilirubinemia) to severe life-threatening anemia (eg, hydrops fetalis).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperbilirubinemia &mdash; Less severely affected infants typically present with unexpected hyperbilirubinemia within the first 24 hours of life. They may also have symptomatic anemia (eg, lethargy or tachycardia) but without signs of circulatory collapse. The degree of anemia varies depending upon the type of HDN. Infants with ABO incompatibility generally have no or only minor anemia at birth. Whereas, infants with Rh or some minor blood group incompatibilities can present with symptomatic anemia that require RBC transfusion. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Anemia'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Hydrops fetalis &mdash; Infants with hydrops fetalis present with skin edema, pleural or pericardial effusion, or ascites. Infants with Rh(D) and some minor blood group incompatibilities, such as Kell, are at risk for hydrops fetalis, especially without antenatal care. ABO alloimmune HDN is generally less severe than that caused by the Rh and Kell systems, however, there are case reports of hydrops fetalis due to ABO incompatibility [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/4\">",
"       4",
"      </a>",
"      ]. Neonates with hydrops fetalis may present at delivery with shock or near shock and require emergent transfusion. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Anemia'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In developed countries, routine antenatal care includes screening for maternal antibodies that can potentially cause alloimmune HDN. If such antibodies are detected, management is directed towards monitoring maternal antibody titers and the condition of the fetus (ie, fetal anemia), and if necessary, intervening with fetal RBC transfusions. Antenatal care and the prevention of maternal Rh sensitization have significantly reduced the number of infants born with severe manifestations of alloimmune HDN. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=see_link\">",
"     \"Prevention of Rh(D) alloimmunization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32982?source=see_link\">",
"     \"Overview of Rhesus (Rh) alloimmunization in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3513?source=see_link\">",
"     \"Significance of minor red blood cell antibodies during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13210?source=see_link\">",
"     \"Intrauterine fetal transfusion of red blood cells\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postnatal management for affected infants is focused on treating the anemia and hyperbilirubinemia caused by hemolysis of neonatal RBCs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Early",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of the anemia at birth is variable. As discussed above, neonates can present with severe HDN (eg, hydrops fetalis) resulting in significant morbidity or death, particularly in the absence of antenatal care. Infants with Rh(D) and some minor blood group incompatibilities, such as Kell, are at risk for hydrops fetalis. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Clinical presentation'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/9/10393?source=see_link\">",
"     \"Postnatal care of hydrops fetalis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The status of a newborn with HDN due to Rh or Kell incompatibility cannot be predicted with certainty at the time of delivery, even if antenatal care has been provided. As a result, delivery room management should anticipate the needs of the most severely affected infant including the ability to emergently transfuse packed group O, Rh(D) negative RBCs in neonates with severe life-threatening anemia.",
"   </p>",
"   <p>",
"    At delivery, assessment includes evaluation of the infant's respiratory and cardiovascular system, and the severity of hemolysis. Pallor, tachycardia, and tachypnea are findings suggestive of symptomatic anemia. Respiratory distress may also be due to pleural effusions or pulmonary hypoplasia in infants with hydrops fetalis. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Clinical presentation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Thoracentesis or paracentesis may be required in infants with significant respiratory distress due to pleural effusions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ascites [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/10\">",
"     10",
"    </a>",
"    ]. Emergent transfusion with group O, Rh(D) negative RBCs is required if the infants is in shock or pending shock due to severe anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/9/10393?source=see_link\">",
"     \"Postnatal care of hydrops fetalis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In all cases if alloimmune HDN is suspected or known, cord blood should be sent for the following [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood type and antiglobulin (Coombs) test to confirm the diagnosis.",
"     </li>",
"     <li>",
"      Hematocrit, reticulocyte count, and bilirubin concentration to guide decisions on therapeutic interventions (eg, transfusions",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      phototherapy).",
"     </li>",
"     <li>",
"      Cross match for subsequent transfusion (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27832?source=see_link&amp;anchor=H15#H15\">",
"       \"Red cell transfusion in infants and children: Selection of blood products\", section on 'Hemolytic disease of the fetus and newborn'",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Transfusion with cross-matched RBC is indicated in infants with symptomatic anemia (eg, lethargy or tachycardia) but who do not have signs of circulatory collapse.",
"   </p>",
"   <p>",
"    In infants with severe anemia and hyperbilirubinemia, exchange transfusion is preferred over simple transfusion because it not only corrects anemia but also reduces hemolysis by replacing antibody-coated neonatal RBCs with donor RBCs, which do not have the sensitizing antigen, and removes a portion of the unbound maternal antibody. In severely hydropic infants, early exchange transfusion appears to also improve oxygenation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/9/10393?source=see_link\">",
"     \"Postnatal care of hydrops fetalis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our criteria for exchange transfusion for hyperbilirubinemia are based upon the American Academy of Pediatrics (AAP) guidelines for the management of hyperbilirubinemia (",
"    <a class=\"graphic graphic_figure graphicRef68219 \" href=\"UTD.htm?20/44/21184\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/11\">",
"     11",
"    </a>",
"    ]. The AAP guidelines for exchange transfusions and a description about the procedure itself including its risk are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Exchange transfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early exchange transfusions require skilled and available personnel to perform the procedure. If there is a delay or inability to perform an exchange transfusion, simple transfusion with packed RBCs may be used recognizing that repeat transfusions may be necessary because of ongoing hemolysis. In addition, the use of intravenous gamma globulin (IVIG) has reduced the need for exchange transfusion especially in infants with ABO hemolytic disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link&amp;anchor=H28#H28\">",
"     \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Intravenous immunoglobulin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our institution, we perform exchange or simple transfusions based upon the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If an infant has severe anemia and hyperbilirubinemia, an exchange transfusion is performed based upon the criteria outlined by the AAP (",
"      <a class=\"graphic graphic_figure graphicRef68219 \" href=\"UTD.htm?20/44/21184\">",
"       figure 1",
"      </a>",
"      ). A simple transfusion may be performed if there is a delay in performing an exchange transfusion.",
"     </li>",
"     <li>",
"      If the hyperbilirubinemia is not severe and the symptoms of anemia are moderate to severe, a simple transfusion is performed.",
"     </li>",
"     <li>",
"      If hyperbilirubinemia is not severe and the symptoms of anemia are mild but the infant is at risk for late anemia, we treat with recombinant erythropoietin (rhEpo) and iron supplementation if the infant is projected to require transfusion without this treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/12\">",
"       12",
"      </a>",
"      ]. However, the indications for and benefits of rhEpo in these patients have not been established, as discussed in the next section. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Late'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The selection of appropriate blood products for RBC transfusions in infants with alloimmune HDN is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27832?source=see_link&amp;anchor=H15#H15\">",
"     \"Red cell transfusion in infants and children: Selection of blood products\", section on 'Hemolytic disease of the fetus and newborn'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the anemia is asymptomatic, interventions to correct the infant's anemia are not required, but exchange transfusion may still be needed because of hyperbilirubinemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Exchange transfusion'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H13\">",
"     'Hyperbilirubinemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Late",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late onset anemia presenting one to three weeks after birth may be seen in neonates with ABO [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/13\">",
"     13",
"    </a>",
"    ], minor blood groups (eg, Gerbich [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/14\">",
"     14",
"    </a>",
"    ] and Kell system [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/15\">",
"     15",
"    </a>",
"    ]), and Rh [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/16\">",
"     16",
"    </a>",
"    ] incompatibilities.",
"   </p>",
"   <p>",
"    Late-onset anemia may be due to immune destruction of erythroid progenitors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/14\">",
"     14",
"    </a>",
"    ]",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    suppression of erythropoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In infants who received intrauterine transfusions, hemolytic anemia may also be delayed until the majority of the donor RBCs is replaced with the RBCs of the affected infant (which express the alloimmune antigen and therefore, are vulnerable to persistent maternal antibody-mediated hemolysis).",
"   </p>",
"   <p>",
"    Treatment options for late-onset anemia are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymptomatic infants are treated with iron supplementation (3 to 6",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      enterally, depending on amount of enteral feeds), and phlebotomy is minimized to reduce blood loss [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Infants with symptomatic late-onset anemia are generally treated with simple transfusion.",
"     </li>",
"     <li>",
"      Recombinant erythropoietin (rhEpo) is sometimes used in selected infants in an effort to reduce or prevent the need for transfusion. This includes infants with Kell, Rh, or ABO incompatibility with progressive anemia but who are not yet sufficiently symptomatic to require transfusion, or families whose religious tradition prohibits transfusion. The rhEpo is given subcutaneously at a dose of 400",
"      <span class=\"nowrap\">",
"       U/kg",
"      </span>",
"      given three times weekly for two weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/12\">",
"       12",
"      </a>",
"      ]. These infants are also treated with supplemental iron (6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for those infants on enteral feedings). Longer courses of rhEpo also may be beneficial [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. Of note, rhEpo treatment does not usually produce an elevation in hematocrit for at least five days [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/12\">",
"       12",
"      </a>",
"      ]. &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The indications for and potential benefits of rhEpo for HDN have not been established. In our practice we use rhEpo in selected infants in an effort to avoid transfusion, as described above. Some other experts do not recommend this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/17\">",
"     17",
"    </a>",
"    ]. The lack of consensus is due to the limited evidence base for use of rhEpo in this population, which consists of case reports with variable results [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/13,15,16,18-20\">",
"     13,15,16,18-20",
"    </a>",
"    ]. In addition, the likelihood of transfusion depends on regional variations in transfusion and phlebotomy practices. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hyperbilirubinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of unconjugated neonatal hyperbilirubinemia is discussed in greater detail separately. The following is a summary of the management of hyperbilirubinemia in infants with alloimmune HDN. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link\">",
"     \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In infants with hyperbilirubinemia due to alloimmune HDN, monitoring serum bilirubin levels, oral hydration, and phototherapy are the mainstays of management. For infants who do not respond to these conventional measures, intravenous fluid supplementation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    exchange transfusion may be necessary to treat hyperbilirubinemia. Intravenous immunoglobulin (IVIG) also may be useful in reducing the need for exchange transfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30038527\">",
"    <span class=\"h3\">",
"     Phototherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phototherapy is the most commonly used intervention to treat and prevent severe hyperbilirubinemia. It is an effective and safe intervention. The AAP has developed guidelines for the initiation and discontinuation of phototherapy based upon total serum bilirubin (TSB) values at specific hourly age of the patient, gestational age, and the presence or absence of risk factors for hyperbilirubinemia including alloimmune HDN (",
"    <a class=\"graphic graphic_figure graphicRef56490 \" href=\"UTD.htm?27/51/28464\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Phototherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30038534\">",
"    <span class=\"h3\">",
"     Hydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phototherapy increases insensible skin losses and as a result the fluid requirements of infants undergoing phototherapy are increased. In addition, by-products of phototherapy are eliminated in the urine. If oral hydration is inadequate, intravenous hydration may be necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Hydration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30038541\">",
"    <span class=\"h3\">",
"     Exchange transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exchange transfusion is used to treat severe anemia, as previously discussed, and severe hyperbilirubinemia. Exchange transfusion removes serum bilirubin and decreases hemolysis by the removal of antibody-coated neonatal RBCs and unbound maternal antibody.",
"   </p>",
"   <p>",
"    Immediate exchange transfusion is recommended if the infant demonstrates signs of acute bilirubin encephalopathy (ABE), such as lethargy, hypotonia, poor sucking, or high-pitched cry. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Exchange transfusion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Acute bilirubin encephalopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal threshold for initiating exchange transfusion in infants with alloimmune HDN to prevent ABE is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/10\">",
"     10",
"    </a>",
"    ]. Based upon clinical practice, a cord bilirubin level greater than 4.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (77",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    has been suggested as an initial threshold for exchange transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/21\">",
"     21",
"    </a>",
"    ]. However, others have suggested that cord bilirubin levels are not useful in predicting postnatal TSB levels in neonates with alloimmune HDN [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/22\">",
"     22",
"    </a>",
"    ]. An alternative method uses a rise of TSB greater than 0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (8",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    per hour, despite intensive phototherapy, as an indication for exchange transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/10,22\">",
"     10,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As discussed above, the AAP has developed guidelines for exchange transfusion based upon TSB values at specific hourly ages of the patient, gestational age, and the presence or absence of risk factors for hyperbilirubinemia including alloimmune HDN (",
"    <a class=\"graphic graphic_figure graphicRef68219 \" href=\"UTD.htm?20/44/21184\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In our practice, we perform an exchange transfusion if the TSB persists above the threshold values outlined by these guidelines after a trial of phototherapy, IVIG, and intravenous hydration (",
"    <a class=\"graphic graphic_figure graphicRef68219 \" href=\"UTD.htm?20/44/21184\">",
"     figure 1",
"    </a>",
"    ). With prenatal diagnosis and management of alloimmune HDN and the use of IVIG, few infants require exchange transfusions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Exchange transfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30038548\">",
"    <span class=\"h3\">",
"     Immunoglobulin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several clinical trials have demonstrated that intravenous immunoglobulin (IVIG) reduces the need for exchange transfusion for hyperbilirubinemia in infants with hemolytic disease caused by Rh or ABO incompatibility [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/23-29\">",
"     23-29",
"    </a>",
"    ]. Although the mechanism of action is uncertain, IVIG is thought to inhibit hemolysis by blocking antibody receptors on RBCs. Limited data exist for its use in other blood group incompatibilities such as anti-C and anti-E disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/24,30\">",
"     24,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We agree with the AAP guidelines, which recommend the administration of IVIG in infants with alloimmune HDN if the TSB is rising despite intensive phototherapy or is within 2 or 3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (34 to 51",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    of the threshold for exchange transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/11\">",
"     11",
"    </a>",
"    ]. The recommended dose is 500 to 1000",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    given over 2 hours, and the dose may be repeated in 12 hours if necessary.",
"   </p>",
"   <p>",
"    The efficacy of IVIG is supported by two systematic reviews, which pooled data from three [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/29\">",
"     29",
"    </a>",
"    ] and four clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/23\">",
"     23",
"    </a>",
"    ]. In the largest trial included in both reviews, IVIG (1000",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose IV) or placebo was randomly assigned to 116 infants with alloimmune HDN. Infants who received IVIG compared with the control group had a lower rate of exchange transfusions (14 versus 38 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/27\">",
"     27",
"    </a>",
"    ]. Similar results were seen in a second randomized controlled trial of 43 infants, in which IVIG was administered at a lower dose (500",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By contrast, a separate single center study in a group of 80 infants with Rh-mediated hemolytic disease showed no effect of IVIG [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/31\">",
"     31",
"    </a>",
"    ]. Treatment of infants with IVIG (750",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    did not reduce the rate of exchange transfusion, duration of phototherapy, or maximum bilirubin level as compared with placebo. The lack of efficacy of IVIG in this study might be specific to the Rh-mediated disease of the study population or might be explained by the relatively low dose of IVIG that was used (750",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for one dose), which is substantially less than the maximum dose recommended by the AAP (up to 1000",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for two doses). These issues warrant additional investigation which may require a large multicenter evaluation. Until more information is available, we continue our current practice of administering IVIG to infants with severe alloimmune HDN according to the AAP guidelines outlined above, in an effort to minimize the need for transfusion support.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although maternal antibodies are present in breast milk, very little antibody is absorbed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10665/abstract/32\">",
"     32",
"    </a>",
"    ]. Thus, mothers should be encouraged to breastfeed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alloimmune hemolytic disease of the newborn (HDN) is caused by the destruction of red cells of the neonate or fetus by maternal IgG antibodies. Incompatibility between mother and offspring of a major blood group (Rhesus [Rh] and ABO) or minor blood group (Kell, Duffy, MNS system, and P system) causes HDN that may result in clinically significant neonatal anemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hyperbilirubinemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical presentation and diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rh HDN &mdash; Although the introduction of Rh immune globulin prophylaxis has significantly reduced sensitization in pregnant Rh-negative women, Rh incompatibility is the most common cause of alloimmune HDN. Clinical manifestations of Rh HDN range from mild, self-limited hemolytic disease to hydrops fetalis. Antenatal care, including intrauterine transfusion, has decreased the rates of neonatal morbidity and mortality due to Rh alloimmune HDN. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Rh hemolytic disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32982?source=see_link\">",
"       \"Overview of Rhesus (Rh) alloimmunization in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ABO HDN &mdash; Infants with ABO HDN generally have less severe disease than those with Rh hemolytic disease. Affected infants are usually asymptomatic at birth and develop hyperbilirubinemia within the first 24 hours of birth. Anemia is usually either absent or mild. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'ABO hemolytic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Minor blood groups &mdash; The clinical disease associated with alloimmune HDN due to minor blood groups ranges from mild (hyperbilirubinemia) to severe manifestations, including hydrops fetalis (",
"      <a class=\"graphic graphic_table graphicRef55421 graphicRef67208 \" href=\"UTD.htm?20/13/20702\">",
"       table 2A-B",
"      </a>",
"      ). In particular, Kell HDN can be severe and may require intrauterine intervention. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Minor blood groups hemolytic disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3513?source=see_link\">",
"       \"Significance of minor red blood cell antibodies during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The diagnosis of alloimmune HDN is based upon demonstrating incompatible blood types between the mother and her infant, and the presence of antibody-mediated hemolysis by either a positive direct or indirect antiglobulin tests (Coombs test), and evidence of hemolysis on a peripheral blood smear of the infant. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis for alloimmune HDN includes other causes of neonatal jaundice",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anemia. Alloimmune HDN is differentiated from these disorders by the presence of a positive direct",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      indirect antiglobulin test. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The degree of anemia varies in infants with alloimmune HDN. Anemia may present at birth (early) or not until one to three weeks of age (late). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In infants with alloimmune HDN, hyperbilirubinemia generally presents within the first 24 hours of life. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In infants with alloimmune HDN with shock or pending shock due to severe anemia, emergent transfusion is required at delivery. We recommend using group O, Rh (D) negative red blood cells (RBCs) versus cross-matched RBCs (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In infants who have early symptomatic anemia without signs of circulatory compromise, we recommend cross-matched RBCs transfusion (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In our institution, we perform exchange or simple transfusions based upon the following considerations: (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Early'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If an infant has severe anemia and hyperbilirubinemia, an exchange transfusion is performed, based upon the criteria outlined by the American Academy of Pediatrics (",
"      <a class=\"graphic graphic_figure graphicRef68219 \" href=\"UTD.htm?20/44/21184\">",
"       figure 1",
"      </a>",
"      ). A simple transfusion may be performed if there is a delay in performing an exchange transfusion.",
"     </li>",
"     <li>",
"      If the hyperbilirubinemia is not severe and the symptoms of anemia are moderate, a simple transfusion is performed.",
"     </li>",
"     <li>",
"      If hyperbilirubinemia is not severe and the symptoms of anemia are mild but the infant is at risk for late anemia, we treat with recombinant erythropoietin (rhEpo) and iron supplementation if the infant is projected to require transfusion without this treatment. However, the indications for and benefits of rhEpo in these patients have not been established. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Late'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In infants with late onset symptomatic anemia, we recommend simple transfusion of cross-matched blood rather than no intervention (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18808?source=see_link&amp;anchor=H4#H4\">",
"       \"Indications for red blood cell transfusion in infants and children\", section on 'Less than 4 months of age'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27832?source=see_link&amp;anchor=H15#H15\">",
"       \"Red cell transfusion in infants and children: Selection of blood products\", section on 'Hemolytic disease of the fetus and newborn'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Management of hyperbilirubinemia due to HDN includes monitoring serum bilirubin levels, oral hydration, and phototherapy, which is based on the criteria outlined by the American Academy of Pediatrics (",
"      <a class=\"graphic graphic_figure graphicRef56490 \" href=\"UTD.htm?27/51/28464\">",
"       figure 2",
"      </a>",
"      ). For infants who do not respond to conventional measures, intravenous fluid supplementation, intravenous immunoglobulin, and exchange transfusion may be used. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link\">",
"       \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H13\">",
"       'Hyperbilirubinemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend immediate exchange transfusion if the infant demonstrates signs of acute bilirubin encephalopathy (ABE) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link\">",
"       \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H13\">",
"       'Hyperbilirubinemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/1\">",
"      Medearis AL, Hensleigh PA, Parks DR, Herzenberg LA. Detection of fetal erythrocytes in maternal blood post partum with the fluorescence-activated cell sorter. Am J Obstet Gynecol 1984; 148:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/2\">",
"      Geifman-Holtzman O, Wojtowycz M, Kosmas E, Artal R. Female alloimmunization with antibodies known to cause hemolytic disease. Obstet Gynecol 1997; 89:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/3\">",
"      Ch&aacute;vez GF, Mulinare J, Edmonds LD. Epidemiology of Rh hemolytic disease of the newborn in the United States. JAMA 1991; 265:3270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/4\">",
"      McDonnell M, Hannam S, Devane SP. Hydrops fetalis due to ABO incompatibility. Arch Dis Child Fetal Neonatal Ed 1998; 78:F220.",
"     </a>",
"    </li>",
"    <li>",
"     McKenzie, S. Anemia In: Intensive Care of the Fetus and Newborn Second Edition, Spitzer AR (Ed), Elsevier Mosby, 2005. p.1289.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/6\">",
"      Bakkeheim E, Bergerud U, Schmidt-Melbye AC, et al. Maternal IgG anti-A and anti-B titres predict outcome in ABO-incompatibility in the neonate. Acta Paediatr 2009; 98:1896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/7\">",
"      Paterakis GS, Lykopoulou L, Papassotiriou J, et al. Flow-cytometric analysis of reticulocytes in normal cord blood. Acta Haematol 1993; 90:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/8\">",
"      Desjardins L, Blajchman MA, Chintu C, et al. The spectrum of ABO hemolytic disease of the newborn infant. J Pediatr 1979; 95:447.",
"     </a>",
"    </li>",
"    <li>",
"     Maisels, MJ. Jaundice. In: Avery's Neonatology: Pathophysiology and Management of the Newborn, McDonald, MG, Mullett, MD, Seshia, MM (Eds), Lippincott, Williams &amp; Williams, Philadelphia 2005. p.800.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/10\">",
"      Peterec SM. Management of neonatal Rh disease. Clin Perinatol 1995; 22:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/11\">",
"      American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/12\">",
"      Calhoun DA, Christensen RD, Edstrom CS, et al. Consistent approaches to procedures and practices in neonatal hematology. Clin Perinatol 2000; 27:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/13\">",
"      Lakatos L, Cs&aacute;thy L, Nemes E. \"Bloodless\" treatment of a Jehovah's Witness infant with ABO hemolytic disease. J Perinatol 1999; 19:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/14\">",
"      Arndt PA, Garratty G, Daniels G, et al. Late onset neonatal anaemia due to maternal anti-Ge: possible association with destruction of eythroid progenitors. Transfus Med 2005; 15:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/15\">",
"      Dhodapkar KM, Blei F. Treatment of hemolytic disease of the newborn caused by anti-Kell antibody with recombinant erythropoietin. J Pediatr Hematol Oncol 2001; 23:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/16\">",
"      Ohls RK. The use of erythropoietin in neonates. Clin Perinatol 2000; 27:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/17\">",
"      Mainie P. Is there a role for erythropoietin in neonatal medicine? Early Hum Dev 2008; 84:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/18\">",
"      Wacker P, Ozsahin H, Stelling MJ, Humbert J. Successful treatment of neonatal rhesus hemolytic anemia with high doses of recombinant human erythropoietin. Pediatr Hematol Oncol 2001; 18:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/19\">",
"      Ovali F, Samanci N, Da��o��lu T. Management of late anemia in Rhesus hemolytic disease: use of recombinant human erythropoietin (a pilot study). Pediatr Res 1996; 39:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/20\">",
"      Pessler F, Hart D. Hyporegenerative anemia associated with Rh hemolytic disease: treatment failure of recombinant erythropoietin. J Pediatr Hematol Oncol 2002; 24:689.",
"     </a>",
"    </li>",
"    <li>",
"     Blanchette, V, Dror, Y, Chan, A. Hematology. In: Avery's Neonatology: Pathophysiology and Management of the Newborn, McDonald, MG, Mullett, MD, Seshia, MM (Eds), Lippincott, Williams &amp; Williams, Philadelphia 2005. p.1169.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/22\">",
"      Wennberg RP, Depp R, Heinrichs WL. Indications for early exchange transfusion in patients with erythroblastosis fetalis. J Pediatr 1978; 92:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/23\">",
"      Gottstein R, Cooke RW. Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed 2003; 88:F6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/24\">",
"      Sato K, Hara T, Kondo T, et al. High-dose intravenous gammaglobulin therapy for neonatal immune haemolytic jaundice due to blood group incompatibility. Acta Paediatr Scand 1991; 80:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/25\">",
"      R&uuml;bo J, Albrecht K, Lasch P, et al. High-dose intravenous immune globulin therapy for hyperbilirubinemia caused by Rh hemolytic disease. J Pediatr 1992; 121:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/26\">",
"      Hammerman C, Kaplan M, Vreman HJ, Stevenson DK. Intravenous immune globulin in neonatal ABO isoimmunization: factors associated with clinical efficacy. Biol Neonate 1996; 70:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/27\">",
"      Alpay F, Sarici SU, Okutan V, et al. High-dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatr 1999; 88:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/28\">",
"      Da��o��lu T, Ovali F, Samanci N, Bengisu E. High-dose intravenous immunoglobulin therapy for rhesus haemolytic disease. J Int Med Res 1995; 23:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/29\">",
"      Alcock GS, Liley H. Immunoglobulin infusion for isoimmune haemolytic jaundice in neonates. Cochrane Database Syst Rev 2002; :CD003313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/30\">",
"      Wagner T, Resch B, Legler TJ, et al. Severe HDN due to anti-Ce that required exchange tranfusion. Transfusion 2000; 40:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/31\">",
"      Smits-Wintjens VE, Walther FJ, Rath ME, et al. Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomized controlled trial. Pediatrics 2011; 127:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10665/abstract/32\">",
"      BOWMAN JM. Gastrointestinal absorption of isohemagglutinin. Am J Dis Child 1963; 105:352.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5933 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-84F2B57B49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_26_10665=[""].join("\n");
var outline_f10_26_10665=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF HDN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Rh hemolytic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ABO hemolytic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Minor blood groups hemolytic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Early",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Late",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30038527\">",
"      - Phototherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30038534\">",
"      - Hydration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30038541\">",
"      - Exchange transfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30038548\">",
"      - Immunoglobulin therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5933\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5933|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/44/21184\" title=\"figure 1\">",
"      TSB guide exchange transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/51/28464\" title=\"figure 2\">",
"      TSB guideline phototherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5933|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/1/27670\" title=\"picture 1\">",
"      Spherocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/61/10199\" title=\"picture 2\">",
"      Elliptocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/28/26054\" title=\"picture 3\">",
"      Heinz body hemolytic anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5933|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/25/12702\" title=\"table 1\">",
"      Non RhD antibodies and HDFN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/4/15437\" title=\"table 2A\">",
"      Minor RBC antibodies pregnancy1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/37/7773\" title=\"table 2B\">",
"      Minor RBC antibodies pregnancy2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=related_link\">",
"      A primer of red blood cell antigens and antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=related_link\">",
"      Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=related_link\">",
"      Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3912?source=related_link\">",
"      Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/16/15623?source=related_link\">",
"      Hereditary elliptocytosis: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20506?source=related_link\">",
"      Hereditary spherocytosis: Clinical features; diagnosis; and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18808?source=related_link\">",
"      Indications for red blood cell transfusion in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/57/13210?source=related_link\">",
"      Intrauterine fetal transfusion of red blood cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32982?source=related_link\">",
"      Overview of Rhesus (Rh) alloimmunization in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=related_link\">",
"      Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/9/10393?source=related_link\">",
"      Postnatal care of hydrops fetalis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40648?source=related_link\">",
"      Prevention of Rh(D) alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/11/27832?source=related_link\">",
"      Red cell transfusion in infants and children: Selection of blood products",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3513?source=related_link\">",
"      Significance of minor red blood cell antibodies during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/9/7318?source=related_link\">",
"      Structure of immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=related_link\">",
"      Treatment of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_26_10666="Amaurosis fugax (transient monocular or binocular visual loss)";
var content_f10_26_10666=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Amaurosis fugax (transient monocular or binocular visual loss)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/26/10666/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/26/10666/contributors\">",
"     Syndee Givre, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/26/10666/contributors\">",
"     Gregory P Van Stavern, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/26/10666/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/26/10666/contributors\">",
"     Paul W Brazis, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/26/10666/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/26/10666/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/26/10666/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/26/10666/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 3, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amaurosis fugax (from the Greek \"amaurosis,\" meaning dark, and the Latin \"fugax,\" meaning fleeting) refers to a transient loss of vision in one or both eyes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/1\">",
"     1",
"    </a>",
"    ]. Varied use of common terminology may cause some confusion when reading the literature. Some suggest that \"amaurosis fugax\" implies a vascular cause for the visual loss [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/2\">",
"     2",
"    </a>",
"    ], but the term continues to be used when describing visual loss from any origin and involving one or both eyes. The term \"transient monocular blindness\" is also often used but is not ideal, since most patients do not experience complete loss of vision with the episode [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/3\">",
"     3",
"    </a>",
"    ]. \"Transient monocular visual loss\" (TMVL) and \"transient binocular visual loss\" (TBVL) are preferred to describe abrupt and temporary loss of vision in one or both eyes, since they carry no connotation regarding etiology.",
"   </p>",
"   <p>",
"    Transient visual loss, either monocular or binocular, reflects a heterogeneous group of disorders, some relatively benign and others with grave neurologic or ophthalmologic implications. The task of the clinician is to use the history and examination to localize the problem to a region in the visual pathways, identify potential etiologies, and, when indicated, perform a focused battery of laboratory tests to confirm or exclude certain causes. Therapeutic interventions and prognostic implications are specific to the underlying cause.",
"   </p>",
"   <p>",
"    This topic discusses transient visual loss. Other ocular and cerebral ischemic syndromes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3882?source=see_link\">",
"     \"Central and branch retinal artery occlusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39273?source=see_link\">",
"     \"Posterior circulation cerebrovascular syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     APPROACH TO TRANSIENT VISUAL LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;By definition, patients with transient visual loss almost always present after the episode has resolved; hence, the neurologic and ophthalmologic examination is usually normal. Reliance is placed on the patient's description of the nature of the visual symptoms and associated features (",
"    <a class=\"graphic graphic_table graphicRef64994 \" href=\"UTD.htm?24/24/24972\">",
"     table 1",
"    </a>",
"    ). Pertinent medical and family history may also provide valuable clues to the underlying diagnosis.",
"   </p>",
"   <p>",
"    Few case series of patients with transient visual loss are reported. Details from the Framingham cohort provide some interesting insights into the challenges of evaluating this symptom. Between 1971 and 1989, participants were systematically questioned regarding specific symptoms of transient ischemic attack (TIA) and stroke; 186 of 2110 subjects reported onset of a sudden visual deficit (not necessarily transient) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/4\">",
"     4",
"    </a>",
"    ]. Follow-up evaluation determined the underlying cause to be stroke or TIA (24 percent), ocular disease (17 percent), transient monocular blindness (10 percent), and migraine (14 percent). The cause remained unknown in 22 percent, and a miscellany of etiologies comprised the remaining 12 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Historical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important historical features include whether the visual loss affected one or both eyes, the duration of the episode, and a specific description of the symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Monocular versus binocular",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important, but often difficult, to establish whether the visual loss was monocular or binocular. Transient monocular visual loss (TMVL) implies a disorder anterior to the optic chiasm (ie, the eye or the optic nerve); possibilities include ocular disease as well as ischemia due to ipsilateral carotid artery disease. Transient binocular visual loss (TBVL) suggests a more posterior process, involving the optic chiasm, tracts, or radiations, or the visual cortex.",
"   </p>",
"   <p>",
"    Patients with homonymous visual field defects often report monocular visual loss and attribute it to the eye with the temporal field cut. The patient should be asked specifically whether each eye was alternately covered during the attack. Impairment of reading suggests that the visual loss was binocular rather than monocular [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/3\">",
"     3",
"    </a>",
"    ]. In practice, many patients are not able to state definitively whether the episode affected one or both eyes. When the history is unclear, the clinician should assume that either a monocular or binocular etiology is possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient visual obscurations due to papilledema typically last seconds. Thromboembolic events from carotid disease or elsewhere generally last 1 to 15 minutes and only rarely an hour or more [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Migraine aura typically lasts 10 to 30 minutes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Description of visual symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient visual loss (TVL) from any cause can be described as mild blurring or fogging to complete blackness, and may involve a part of or all of the visual field. As an example, patients with ocular ischemia may lose the upper or lower half of vision, the temporal or nasal aspect of vision, small areas of vision centrally or paracentrally, and the entire visual field [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/5,8,9\">",
"     5,8,9",
"    </a>",
"    ]. TMVL descending over the field of vision (like a curtain or shade) or, less commonly, ascending from below, is highly suggestive of retinal ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/5,8,9\">",
"     5,8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Positive visual phenomena, such as photopsias or scintillations that march across the visual field, suggest migraine as the most likely diagnosis. Seizures affecting visual cortex often involve positive visual symptoms, but are typically maximal at onset and lack the evolution or build-up characteristic of migraine. While the visual symptoms produced by retinal ischemia are usually \"negative\" (eg, shaded, black, blurred), positive symptoms are also known to occur in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/5,10,11\">",
"     5,10,11",
"    </a>",
"    ]. Similarly, migraine can produce visual loss without scintillations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Patients who experience intermittent hyphema (hemorrhage within the anterior chamber) may remark that the visual field appears red (erythropsia) during the episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Precipitating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe carotid occlusive disease has been associated with dimming of vision in one eye after exposure to bright light (retinal claudication) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/5,11,15-17\">",
"     5,11,15-17",
"    </a>",
"    ]. Alternating transient visual loss to bright light has also been described in two patients with giant cell arteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/18\">",
"     18",
"    </a>",
"    ]. Other retinal diseases (eg, photoreceptor dystrophy, macular degeneration) are also associated with transient worsening of vision in bright light. The mechanism is believed to be related to an ischemia-induced delay in regenerating visual pigments in the photoreceptors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Episodes of TMVL due to carotid stenosis may be induced by changes in posture or neck position that temporarily reduce blood flow through the artery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/11\">",
"     11",
"    </a>",
"    ]. Postprandial TMVL has been described in severe carotid narrowing, presumably as a vascular steal phenomenon [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/15,19\">",
"     15,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TMVL occurring when the eye is moved into certain positions of gaze (gaze-evoked amaurosis) is suggestive of an orbital mass and is thought to be due to interruption of blood flow to the retina, choroid, or optic nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Loss of vision after exercise or a hot shower (Uhthoff's symptom) is characteristic of demyelinating disease of the optic nerve. Exercise has also been reported to induce retinal vasospasm [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The transient visual obscurations of papilledema are sometimes brought on by postural change, exercise, or straining.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with TVL from vasospasm, migraine, or ischemia may have multiple episodes separated by minutes or years. In one study, a high number of recurrent episodes (&gt;10) of TMVL was more likely to be associated with complete rather than incomplete or absent occlusion of the ipsilateral internal carotid artery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/5\">",
"     5",
"    </a>",
"    ]. However, multiple, stereotypic episodes of TMVL recurring over many years in the absence of stroke or permanent visual loss would suggest a more benign etiology such as migraine or vasospasm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Associated symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;TVL due to thromboembolic disease is painless in the vast majority of patients. The association of TVL with headache or periocular pain should alert the examiner to check for other causes such as migraine, angle closure glaucoma, and giant cell arteritis.",
"   </p>",
"   <p>",
"    The association of TVL with transient contralateral hemiplegia is strongly suggestive of severe carotid occlusive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/6,19\">",
"     6,19",
"    </a>",
"    ]. Vertebrobasilar symptoms (vertigo, dysarthria, diplopia) should suggest posterior circulation ischemia. Visual loss in the latter setting is binocular, but patients may misreport a transient hemianopia as monocular vision loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older age, a medical history of diabetes mellitus, hypertension, or hyperlipidemia all suggest atherosclerotic vascular disease. Known cardiac disease might indicate a cardioembolic event. A history of rash and previous miscarriage is a feature of the antiphospholipid antibody syndrome, which may uncommonly cause TVL. A family history of stroke at a young age or unexplained thrombosis might prompt evaluation for an underlying hereditary hypercoagulable disorder. A history of typical migraine headaches in the patient or family member suggests migraine as a cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The examination should include testing of visual acuity and visual fields, and examination of the optic fundus. The techniques employed are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link&amp;anchor=H18#H18\">",
"     \"The detailed neurologic examination in adults\", section on 'Vision (CN II)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fundoscopic examination should include careful observation of the optic disc, retina, and blood vessels for clues as to the origin of the visual symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disc swelling in the setting of TMVL suggests an acute event involving the optic nerve, usually ischemia or inflammation. Because optic disc pallor does not develop until four to six weeks after an injury, its presence suggests a subacute or chronic process, rather than an acute event. Bilateral disc swelling with good visual acuity should prompt an evaluation for papilledema. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30552?source=see_link\">",
"       \"Overview and differential diagnosis of papilledema\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Retinal whitening often reflects ischemia of the inner retina, and may be seen after a branch or central retinal artery occlusion (",
"      <a class=\"graphic graphic_picture graphicRef60171 \" href=\"UTD.htm?38/33/39454\">",
"       picture 1",
"      </a>",
"      ). Mid-peripheral hemorrhages, tortuous veins, and neovascularization reflect reduced retinal arterial flow and venous stasis as the result of severe carotid stenosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3882?source=see_link\">",
"       \"Central and branch retinal artery occlusion\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Examination of the arterioles should focus on caliber as well as the presence of embolic plaques. Investigators have attempted to identify the origin of retinal plaques by their appearance, but in practice the distinction is often difficult. A Hollenhorst plaque typically appears at vascular bifurcations, and has a highly refractile appearance (",
"      <a class=\"graphic graphic_picture graphicRef63740 \" href=\"UTD.htm?23/3/23601\">",
"       picture 2",
"      </a>",
"      ). It strongly suggests ipsilateral carotid artery disease, but these cholesterol emboli may also arise from a more proximal source, such as the aortic arch [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/23\">",
"       23",
"      </a>",
"      ]. Platelet-fibrin and calcific emboli are less commonly seen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A detailed eye examination usually requires an ophthalmology consult, which is indicated in many cases of TVL (see",
"    <a class=\"local\" href=\"#H28\">",
"     'Diagnostic evaluation of transient visual loss'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CAUSES OF TRANSIENT MONOCULAR VISUAL LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemia is the most common cause of transient monocular visual loss (TMVL); this in itself can have diverse etiologies. Papilledema, optic neuropathy, and ocular disease are other causes of TMVL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis and pathophysiology for TMVL of ischemic origin are diverse, and include large artery occlusive disease (atherothrombosis, embolus, dissection), small artery occlusive disease (anterior ischemic optic neuropathy, vasculitis), venous disease, cardiac disease, hypercoagulable disorders, and systemic hypoperfusion. The final common pathway for these disorders is ischemia to the retina, the optic nerve, or both. TMVL secondary to retinal ischemia from carotid disease may be due to either embolism or hypoperfusion from fixed arterial stenosis, whereas optic nerve ischemia usually results from the latter mechanism.",
"   </p>",
"   <p>",
"    Most patients with TMVL attributable to ischemia will report areas of blank or fuzzy vision (\"negative visual phenomena\"). Less common, but not unusual, are reports of positive visual phenomena. Symptoms generally begin abruptly and reach maximum severity within the first few minutes.",
"   </p>",
"   <p>",
"    Funduscopic examination may be normal or may show evidence of vascular disease: cotton wool spots, retinal emboli, retinal hemorrhages, retinal whitening, or dilated retinal veins (",
"    <a class=\"graphic graphic_picture graphicRef60171 \" href=\"UTD.htm?38/33/39454\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef63740 \" href=\"UTD.htm?23/3/23601\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Retinal embolism is frequently asymptomatic. In a population-based study of approximately 2000 older adults (&ge;49 years) whose retinas were examined at five and ten years, there was a baseline prevalence of retinal emboli of 1.4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/24\">",
"     24",
"    </a>",
"    ]. The cumulative 10-year incidence was 3 percent. Over 10 years follow-up, all-cause and stroke-related mortality was somewhat higher in patients with documented retinal emboli (HR = 1.3; CI 1.0 to 1.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Carotid artery disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic visual loss related to occlusive disease in the cervical carotid artery may result from thromboembolism or hypoperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/8,10\">",
"     8,10",
"    </a>",
"    ]. The former mechanism is believed to be more common [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/12,26\">",
"     12,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to transient ischemic attacks (TIAs) involving the cerebral hemispheres, retinal ischemia is more commonly associated with emboli originating from carotid stenosis rather than heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. This may represent a streaming effect of laminar blood flow, whereby particulates of uniform size are consistently deposited into one lamina, and swept into the same distal vascular bed. Small emboli from carotid disease may be more likely to drift to the edge of the bloodstream and enter the ophthalmic artery. Also, these small particles may be more prone to obstruct the smaller retinal arterioles.",
"   </p>",
"   <p>",
"    Severe stenosis (90 to 100 percent) of the ipsilateral carotid artery may also cause visual loss due to retinal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    choroidal hypoperfusion from low limiting stenosis. This ischemic mechanism may be more likely to include positive visual phenomena and recurrent episodes than thromboembolism, and it is often induced by activities that reduce ocular perfusion pressure (such as postural change, postprandial vascular steal) or increase retinal oxygen demand (such as exposure to bright light) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/5,8,11,17,19,26\">",
"     5,8,11,17,19,26",
"    </a>",
"    ]. In contrast, episodes of TMVL due to carotid artery thromboembolism usually occur spontaneously, and are more often isolated events, although they can recur [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Visual loss caused by either mechanism typically encompasses the entire visual field, but may affect only the upper, lower, nasal, or temporal portion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/2,7,8,10\">",
"     2,7,8,10",
"    </a>",
"    ]. Small central or paracentral scotomas can also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/8\">",
"     8",
"    </a>",
"    ]. The classic description of a \"curtain\" or \"shade\" descending over vision, is relatively uncommon; in one large study, only 23.8 percent of patients with TMVL experienced altitudinal visual loss [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/30\">",
"     30",
"    </a>",
"    ]. Nonetheless, when this is described, it is highly suggestive of retinal embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/31\">",
"     31",
"    </a>",
"    ]. Patients may also experience gradual graying of vision that progresses from the periphery to the center [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/10,11,31\">",
"     10,11,31",
"    </a>",
"    ]. The visual loss may be associated with scintillations or the sensation of color [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/8,12\">",
"     8,12",
"    </a>",
"    ]. Episodes generally last from seconds to minutes, rarely more than 15 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/2,5,7,8,10\">",
"     2,5,7,8,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When contralateral hemispheric symptoms (motor, sensory, aphasia) accompany visual loss, carotid disease is very likely; however, TMVL is more often an isolated symptom [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a prospective study of 337 patients with TMVL, clinical features most predictive of high-grade (&gt;70 percent) carotid stenosis included rapid onset of symptoms, altitudinal pattern of onset or resolution, and a duration of 1 to 10 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of carotid disease in the setting of TMVL is important because of the implications for stroke risk, approximately 2 to 3 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/32\">",
"     32",
"    </a>",
"    ]. Most of these strokes are large-vessel infarcts within the territory of the ipsilateral carotid artery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/33\">",
"     33",
"    </a>",
"    ]. Compared with cerebral ischemia, TMVL carries a lower risk for stroke in the setting of high-grade carotid disease; but still identifies a high-risk population for which carotid endarterectomy may be beneficial, particularly in high-risk subgroups [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/29,34\">",
"     29,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21530?source=see_link&amp;anchor=H15#H15\">",
"     \"Management of symptomatic carotid atherosclerotic disease\", section on 'Retinal versus hemispheric ischemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Giant cell arteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;TMVL, similar in character to that associated with carotid disease, can occur in patients with giant cell arteritis (GCA) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Occlusion or near occlusion of the posterior ciliary arteries by granulomatous inflammation within the artery wall can cause an anterior ischemic optic neuropathy. Posterior ischemic optic neuropathy and central retinal artery occlusion are also manifestations of GCA.",
"   </p>",
"   <p>",
"    GCA most often presents as acute sustained unilateral visual loss with a swollen optic disc [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/35\">",
"     35",
"    </a>",
"    ]. In two large series (each &gt;150 patients) of biopsy-confirmed GCA, TVL was the presenting symptom in just 10 to 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/35,37\">",
"     35,37",
"    </a>",
"    ]. It was bilateral in 27 to 35 percent of these. Common accompanying symptoms include jaw claudication and headache (each in about half of patients). However, patients with occult giant cell arteritis may have no other symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While TVL is a relatively uncommon presentation for GCA, it represents an opportunity for intervention to prevent permanent visual loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34217?source=see_link\">",
"     \"Treatment of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Other ischemic etiologies",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiogenic embolism &mdash; Emboli from the heart and great vessels may lodge in the ophthalmic circulation and cause TMVL, which is clinically similar to that associated with carotid disease. Cardiogenic embolism is less likely to underlie TMVL than a cerebral TIA.",
"      <br/>",
"      <br/>",
"      While an uncommon cause of TMVL, cardiogenic embolism is important to identify in this setting, because anticoagulation is often recommended to prevent more serious sequelae. A detailed review of cardiogenic sources of emboli is presented elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9208?source=see_link&amp;anchor=H7#H7\">",
"       \"Etiology and classification of stroke\", section on 'Embolism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypotension &mdash; Hypoperfusion from cardiac failure and hypovolemia, reduced cardiac output from a dysrhythmia, and orthostatic hypotension may cause TVL [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/10-12,26\">",
"       10-12,26",
"      </a>",
"      ]. Anemia and intradialysis hypotension have also been implicated [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. In this setting, visual loss is usually binocular and associated with other suggestive features, such as postural change, lightheadedness, and presyncope. However, orthostatic or systemic hypotension can result in hypoperfusion to one eye, usually in association with carotid occlusive disease, which results in selective hypoperfusion to the ipsilateral eye [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]. TMVL may also be precipitated by hypotension in the setting of underlying retinopathy, optic neuropathy, or glaucoma [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/39,42,43\">",
"       39,42,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Coagulopathy &mdash; Patients with coagulation disorders may have episodes of TMVL, with characteristics similar to those caused by atheromatous disease [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/42,44,45\">",
"       42,44,45",
"      </a>",
"      ]. Patients with coagulopathies usually have other symptoms in addition to TMVL (eg, rash associated with the antiphospholipid antibody syndrome)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a medical history of other coagulation-related problems. However, there have been reports of patients with TMVL as the presenting symptom of a coagulation disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/45,46\">",
"       45,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Others &mdash; Nonarteritic anterior ischemic optic neuropathy is more common than giant cell arteritis and is associated with small artery disease. However, it is not typically preceded by transient episodes of visual loss, and therefore is not usually considered in the differential diagnosis of TMVL [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/58/27558?source=see_link&amp;anchor=H2#H2\">",
"       \"Nonarteritic anterior ischemic optic neuropathy: Clinical features and diagnosis\", section on 'Symptoms'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Atherosclerosis involving the intracranial carotid or the ophthalmic artery may also produce TMVL [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/48\">",
"       48",
"      </a>",
"      ]. TMVL also occurs in nonatheromatous disease of the carotid, such as fibromuscular dysplasia, aneurysm, dissection, and arteritis, such as Wegener's granulomatosis and Takayasu's arteritis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/26,49\">",
"       26,49",
"      </a>",
"      ]. Cocaine and other illicit drugs have been associated with TMVL through vasospasm or other mechanisms [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/50-52\">",
"       50-52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Retinal vein occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;TMVL may occur as a premonitory symptom of central retinal vein occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/10,53,54\">",
"     10,53,54",
"    </a>",
"    ]. Occlusion or thrombosis of the central retinal vein is associated with chronic glaucoma, atherosclerotic risk factors (age, diabetes, hypertension), hyperviscosity, and coagulopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. The cause of retinal vein occlusion is often unknown.",
"   </p>",
"   <p>",
"    Episodes of visual loss are quite variable in length and may last several hours. Another potentially distinguishing feature is the description of \"cloudy vision\" rather than visual loss; however, episodes may be entirely similar to those occurring in arterial ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/54,56\">",
"     54,56",
"    </a>",
"    ]. It is more common, however for retinal vein occlusion to have a subacute presentation of fixed vision loss.",
"   </p>",
"   <p>",
"    Some speculate that venous congestion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reflux may also play a role in some cases of idiopathic TMVL (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Idiopathic'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Retinal vasospasm and retinal migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic, reversible vasospasm affecting blood vessels in the retina and causing TMVL is a commonly described, but poorly understood and somewhat controversial phenomenon. Reported observations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Studies of children, adolescents, and young adults with TMVL have shown that a majority have headaches either associated with or between episodes, a personal or family history of migraines, and a benign course [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/2,4,58,59\">",
"       2,4,58,59",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Transient arterial narrowing has been observed in retinal arteries in symptomatic patients [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/60-63\">",
"       60-63",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Some patients' symptoms respond to calcium channel blockers [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/61-63\">",
"       61-63",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some of these observations have led to this entity being called retinal migraine. Retinal migraine is a diagnosis included in the International Headache Society Criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/64\">",
"     64",
"    </a>",
"    ], but is a debatable entity, and is always considered a diagnosis of exclusion. The formal criteria require reversible positive or negative visual phenomena accompanied or followed within 60 minutes by migraine headache. A personal or family history of migraine may suggest the diagnosis in the absence of headache. In general, migraine as a cause of TVL is best accepted as a manifestation of occipital cortex involvement, producing binocular, usually positive, visual symptoms, the \"classic\" or typical migraine aura. The etiology in this case is presumed to be a cortical spreading depression and not vasospasm. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Migraine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Important caveats in the diagnosis of retinal vasospasm are that not all arterial narrowing is vasospasm; proximal occlusive disease and low blood flow may also give this appearance. Also, vasospasm may occur secondary to an underlying disease, such as vasculitis, migraine, hypercoagulability, or cocaine use [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/12,35,50,65,66\">",
"     12,35,50,65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Symptoms described in retinal vasospasm include characteristic positive phenomena of scintillations and photopsias as well as primarily negative symptoms&mdash;black, gray, white, or shaded areas, which are indistinguishable from ischemic symptoms. Patients may have several episodes in one day. A typical episode lasts longer than five minutes and less than 60 minutes. A first episode usually occurs in individuals less than 40 years old.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Optic neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a chronic optic neuropathy will occasionally complain of episodes of transient loss or blurring of vision, usually in association with elevation of body temperature (hot shower, exercise). This phenomenon is termed Uhthoff's symptom and reflects temporary conduction block along a previously demyelinated optic nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The episodes typically last several minutes, but occasionally longer, until the body temperature returns to normal. Uhthoff's phenomenon is classically associated with multiple sclerosis, but has been reported in other optic neuropathies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology and clinical features of multiple sclerosis in adults\", section on 'Optic neuritis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=see_link&amp;anchor=H21#H21\">",
"     \"Epidemiology and clinical features of multiple sclerosis in adults\", section on 'Heat sensitivity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Papilledema",
"    </span>",
"    &nbsp;&mdash;&nbsp;While rarely the presenting symptom, transient visual obscurations are common in patients with papilledema. These are described as a \"whiting\" or \"graying out\" of part or all of the visual field; they are often unilateral, and typically very brief (just seconds) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/40,70,71\">",
"     40,70,71",
"    </a>",
"    ]. They may occur spontaneously or with changes in position, and they are believed to represent transient fluctuations in nerve head perfusion. Other symptoms and signs (eg, headache, bilateral disc swelling) are usually present to suggest this diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17417?source=see_link\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30552?source=see_link\">",
"     \"Overview and differential diagnosis of papilledema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Optic nerve compression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gaze-evoked amaurosis has been described in association with compressive optic neuropathies from tumors, trauma, Graves' ophthalmopathy, and other causes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. In cases due to slow growing masses, the examination will often reflect ipsilateral optic nerve dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Ocular causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular causes of TMVL include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased intraocular pressure such as from intermittent angle closure glaucoma is typically associated with eye pain [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/43,74\">",
"       43,74",
"      </a>",
"      ]. A complaint of halos around lights is common in this condition.",
"     </li>",
"     <li>",
"      Spontaneous hyphema (hemorrhage within the anterior chamber) can occur after cataract surgery with lens implantation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/12,14,75\">",
"       12,14,75",
"      </a>",
"      ]. The symptoms of the hyphema may be visual loss and erythropsia.",
"     </li>",
"     <li>",
"      Vitreous floaters occasionally obscure central vision.",
"     </li>",
"     <li>",
"      Congenital optic disc anomalies and optic disc drusen have been associated with TMVL.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clues to an ocular cause might include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Eye redness",
"     </li>",
"     <li>",
"      Pain and tearing associated with visual loss (intermittent angle closure glaucoma)",
"     </li>",
"     <li>",
"      More prolonged episodes [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Relief of symptoms with blinking or rubbing the eye (dry eye)",
"     </li>",
"     <li>",
"      Squinting (refractive error)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Idiopathic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite extensive workups, a cause of TMVL will not be found in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/12,26\">",
"     12,26",
"    </a>",
"    ]. These patients are at very low risk for either permanent visual loss or stroke and should be reassured.",
"   </p>",
"   <p>",
"    In one study, a higher proportion of 134 patients with TMVL were found to have doppler evidence of jugular venous reflux compared with controls (57 versus 30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/76\">",
"     76",
"    </a>",
"    ]. This was present in an even higher proportion (74 percent) of those with recurrent events of undetermined cause suggesting that venous congestion may play a role in some cases of idiopathic TMVL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     CAUSES OF TRANSIENT BINOCULAR VISUAL LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient binocular visual loss (TBVL) implies a process posterior to the optic chiasm, and may include migraine, seizure, and vertebrobasilar ischemia. Typical clinical features are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef64994 \" href=\"UTD.htm?24/24/24972\">",
"     table 1",
"    </a>",
"    ). In rare cases, TBVL may reflect bilateral, simultaneous involvement of the anterior visual pathways such as might occur with giant cell arteritis and systemic hypotension, as discussed above. Papilledema can produce unilateral or bilateral transient visual obscurations, also discussed above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine is the most common cause of TBVL in young adults. Positive visual phenomena such as scintillations suggest migraine as the most likely diagnosis, especially if there is a history of headaches with migrainous features. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/36/42569?source=see_link\">",
"     \"Approach to the patient with visual hallucinations\"",
"    </a>",
"    .) This classic or typical migraine aura typically lasts 20 to 30 minutes, rarely as long as an hour, and has a characteristic build-up, or evolution, a feature lacking in other causes of TBVL (ischemia, seizure) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/77\">",
"     77",
"    </a>",
"    ]. The mechanism of visual loss in migraine is thought to be neuronal depression after a period of cortical excitation (\"spreading depression of Leao\") [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link&amp;anchor=H203275055#H203275055\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Migraine aura'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link&amp;anchor=H130649620#H130649620\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Migraine visual aura may occur independently of headache (sometimes called migraine equivalent or acephalgic migraine) and may be confused with ischemia, especially in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/13\">",
"     13",
"    </a>",
"    ]. In a Danish study, 38 percent of 163 patients reported having attacks of migraine aura both with and without headache; 4 percent had migraine aura that never occurred with headache [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/79\">",
"     79",
"    </a>",
"    ]. The diagnosis of acephalgic migraine is supported by positive, binocular visual symptoms, a somewhat longer duration of episodes than is typical for ischemia, and a personal or strong family history of migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from the Framingham cohort suggest that migrainous visual aura is not rare, even in older adults. In that study, 1.2 percent of individuals aged 50 to 82 years reported visual symptoms, subsequently attributed to migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/80\">",
"     80",
"    </a>",
"    ]. In most (77 percent) of these 26 patients, the onset of these symptoms occurred after age 50 years; most episodes were never associated with headache (58 percent), and 42 percent had no history of recurrent headaches. Three strokes occurred subsequently in these 26 patients; this 11.5 percent incidence was lower than the 33 percent incidence among patients with transient ischemic attack (TIA).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Seizure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visual seizure is an uncommon cause of TBVL. The visual loss may be ictal or postictal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23578?source=see_link&amp;anchor=H13#H13\">",
"     \"Localization-related (partial) epilepsy: Causes and clinical features\", section on 'Occipital lobe epilepsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among 20 patients in one series of epileptic visual aura, symptoms included elementary hallucinations (eg, flickering lights, stars, flashes of light) and visual loss, which was described as blurred vision, \"white out,\" or scotomata [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/81\">",
"     81",
"    </a>",
"    ]. The visual loss and hallucinations could start in a specific part of the visual field, could move or be stationary, or could involve the entire visual field. These symptoms were not specifically localizing; underlying lesions (present in all) were found in either the occipital or temporal lobes. Ictal blindness may be an isolated epileptic phenomenon, but is more usually accompanied by other manifestations, such as tonic eye deviation, altered consciousness, or motor impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/82\">",
"     82",
"    </a>",
"    ]. Prolonged ictal blindness (\"status epilepticus amauroticus\") is rarely reported [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postictal blindness typically lasts minutes to hours, but may last days or weeks. As with Todd's paralysis (postictal weakness following a motor seizure), the mechanism is presumed to be prolonged enhancement of inhibitory stimuli in response to prolonged excitation (similar in some ways to migraine).",
"   </p>",
"   <p>",
"    Adult onset visual seizures may be associated with cortical lesions in the posterior visual pathways, which produce a corresponding visual field defect. Therefore, visual field testing (preferably using static or kinetic perimetry) is important in all patients with TBVL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Vertebrobasilar ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemia to the visual cortex may result in TBVL. If only one hemisphere is ischemic, the patient will experience homonymous visual field loss contralateral to the lesion. Visual loss may be an isolated symptom or may be accompanied by symptoms of brainstem ischemia (dysarthria, dysphagia, vertigo, diplopia) or cerebral ischemia (hemiparesis, hemisensory loss, aphasia). Isolated visual symptoms are usually the result of occipital lobe ischemia secondary to posterior cerebral artery occlusion. Difficulty seeing to one side is the most common symptom; lateralized flashing lights (photopsias) are also common [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with anterior circulation ischemia, the mechanism of strokes in the posterior circulation may involve thrombosis, embolism, or hypoperfusion from fixed arterial stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/86\">",
"     86",
"    </a>",
"    ]. The most common identified mechanism underlying posterior cerebral artery territory infarcts is embolism, usually from cardiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. Artery to artery embolism, usually originating from proximal disease in the vertebral arteries, accounts for the second highest percentage. Atherostenosis in the posterior cerebral arteries has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39273?source=see_link&amp;anchor=H28#H28\">",
"     \"Posterior circulation cerebrovascular syndromes\", section on 'Posterior cerebral arteries'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION OF TRANSIENT VISUAL LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic workup is tailored to the likely responsible conditions as suggested by the history and physical examination (",
"    <a class=\"graphic graphic_table graphicRef64994 \" href=\"UTD.htm?24/24/24972\">",
"     table 1",
"    </a>",
"    ). The overlap in clinical presentations and grave prognosis of some potential diagnoses require that some diagnostic testing is performed in most patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ophthalmologic evaluation &mdash; A detailed funduscopic evaluation is an important part of the evaluation of patients with transient visual loss. Ophthalmology referral is required for all patients with suspected giant cell arteritis, retinal vein disease, and ocular causes of visual loss, and will often reveal evidence of an otherwise unsuspected ischemic mechanism in patients with recurrent episodes of TMVL.",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate and C-reactive protein - All older patients (&gt;50 years) with transient monocular or binocular vision loss should have a sedimentation rate and C-reactive protein to exclude giant cell arteritis (GCA). If these are elevated, or if the history is very suggestive, patients should proceed to a confirmatory temporal artery biopsy. Treatment should not await pathology results. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link\">",
"       \"Clinical manifestations of giant cell (temporal) arteritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34217?source=see_link\">",
"       \"Treatment of giant cell (temporal) arteritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Carotid imaging &mdash; Carotid duplex ultrasound, magnetic resonance angiography, or computed tomographic angiography should be ordered in all older patients (&gt;50 years) and in younger patients with vascular risk factors (diabetes, hypertension, hyperlipidemia) who have experienced TMVL. Magnetic resonance imaging (MRI) should be performed in a patient of any age with TMVL who has a history suggestive of carotid artery dissection [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/86\">",
"       86",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Further evaluation and treatment of carotid disease in the setting of TMVL is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=see_link\">",
"       \"Evaluation of carotid artery stenosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21530?source=see_link&amp;anchor=H15#H15\">",
"       \"Management of symptomatic carotid atherosclerotic disease\", section on 'Retinal versus hemispheric ischemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiac evaluation &mdash; Once GCA and carotid disease have been excluded, an evaluation to seek a cardiogenic source of embolism should follow in all older patients (as well as in younger patients with risk factors) who have had TMVL. This is also indicated in patients with TBVL due to posterior circulation ischemia. Testing may include Holter monitoring and echocardiography [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/89\">",
"       89",
"      </a>",
"      ]. The details of this evaluation are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=see_link&amp;anchor=H35#H35\">",
"       \"Overview of the evaluation of stroke\", section on 'Cardiac evaluation'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A baseline electrocardiogram (ECG) should also be included in the evaluation of these patients as cardiac morbidity and mortality in patients with TMVL and central retinal artery occlusion is significant [",
"      <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/16,29,90\">",
"       16,29,90",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Brain MRI &mdash; Older patients with binocular visual symptoms (TBVL) that accompany symptoms suggestive of vertebrobasilar ischemia, should have a brain MRI. Diffusion-weighted imaging (DWI) increases the yield of abnormalities in patients with TIA, and intracranial and cervical magnetic resonance angiography (MRA) may turn up occlusive disease of the posterior circulation.",
"      <br/>",
"      <br/>",
"      Patients whose history or examination suggests optic neuropathy should have an MRI to look for other evidence of demyelinating disease. A history suggestive of compressive optic neuropathy (gaze evoked amaurosis) or seizure should also prompt a brain MRI with contrast enhancement.",
"     </li>",
"     <li>",
"      EEG &mdash; Electroencephalography (EEG) is not a routine test for TVL, but should be undertaken in a patient with TBVL whose symptoms suggest possible seizure. EEG monitoring may increase the diagnostic yield, especially in patients with frequently recurring symptoms.",
"     </li>",
"     <li>",
"      Hypercoagulable testing &mdash; When brain or ocular ischemia is the suspected cause of TVL, hypercoagulable testing should be performed in individuals who have suggestive histories (prior thrombosis, miscarriage, or family history), as well as in individuals with probable ischemia and otherwise negative workup. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link&amp;anchor=H25#H25\">",
"       \"Evaluation of the patient with established venous thrombosis\", section on 'Choice of coagulation tests'",
"      </a>",
"      .) A complete blood count should also be obtained to screen for conditions such as polycythemia vera and essential thrombocythemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Young patients without risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients in whom there is a strong presumptive diagnosis of migraine may have a somewhat limited workup or perhaps no testing at all. An example might be a young person with typical binocular visual symptoms that include positive phenomena and are followed by migraine headache. Other factors that support (but obviously do not confirm) a diagnosis of migraine include a family history of migraine and a past history of migraine headaches. The more the symptoms deviate from classic migraine, the more extensive the workup should be.",
"   </p>",
"   <p>",
"    In the majority of young patients (&lt;50 years) with TMVL who are otherwise healthy, the diagnostic yield of extensive testing is very low [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/4,91\">",
"     4,91",
"    </a>",
"    ]. The most reasonable presumed cause is vasospasm or migraine, although this remains speculative. Their future risk of stroke is low [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/92\">",
"     92",
"    </a>",
"    ]. However, TMVL due to carotid disease and cardiac disease does occur in young people [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/3,90\">",
"     3,90",
"    </a>",
"    ]. The extent to which these patients should be subjected to diagnostic investigation is debated, and should be decided individually. A conservative approach recommends performing noninvasive studies that identify high-risk pathology. This might include MRI, carotid imaging, ECG, echocardiography, and selective clotting studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/26/10666/abstract/1,3,69,90\">",
"     1,3,69,90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Underlying causes of transient visual loss range from benign conditions to those with serious neurologic and ophthalmologic sequelae.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With transient symptoms, the diagnosis is guided by historical features. The most important of these is the distinction between monocular and binocular involvement; however, this is often unclear. Other helpful features include symptom duration, description of symptom onset, the presence of positive visual phenomena, precipitating factors, and associated symptoms (",
"      <a class=\"graphic graphic_table graphicRef64994 \" href=\"UTD.htm?24/24/24972\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Historical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ischemia originating from carotid artery disease is a common cause of transient monocular visual loss (TMVL), and has serious implications for future stroke risk that can be reduced by carotid endarterectomy. Suggestive features include rapid onset in an altitudinal pattern (visual loss descending over the field of vision like a curtain or shade) and brief duration (&lt;10 minutes). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Carotid artery disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Giant cell arteritis is not a common cause of TMVL but is a treatable cause of otherwise permanent visual loss. It is clinically indistinguishable from TMVL of carotid disease except for frequent accompanying headache. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Giant cell arteritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other causes of TMVL include ischemia from cardioembolic disease, some ocular conditions, and others. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Causes of transient monocular visual loss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TMVL in young patients may be due to retinal vasospasm or may be idiopathic, but other etiologies must be excluded. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Retinal vasospasm and retinal migraine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Migraine typically produces binocular symptoms with positive phenomenology and a characteristic build-up, lasting 10 to 30 minutes, and associated with or followed by migraine headache. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Migraine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Binocular visual loss, usually isolated to one visual field, can also occur during vertebrobasilar ischemia or seizure. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Causes of transient binocular visual loss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Unless symptoms are very typical for migraine, some diagnostic testing is required. Erythrocyte sedimentation rate and C-reactive protein should be performed in all individuals over age 50 years with transient monocular or binocular visual loss. We recommend ophthalmologic examination and carotid duplex ultrasound for all patients with TMVL. Other tests are ordered according to symptoms and clinical setting and may include cardiac workup, hypercoagulable testing, magnetic resonance imaging (MRI), and electroencephalogram (EEG) (",
"      <a class=\"graphic graphic_table graphicRef78246 \" href=\"UTD.htm?38/26/39339\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Diagnostic evaluation of transient visual loss'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Bernstein EF. Amaurosis fugax, Springer-Verlag, New York 1987. p.286.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/2\">",
"      Fisher CM. 'Transient monocular blindness' versus 'amaurosis fugax'. Neurology 1989; 39:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/3\">",
"      Biousse V, Trobe JD. Transient monocular visual loss. Am J Ophthalmol 2005; 140:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/4\">",
"      Tippin J, Corbett JJ, Kerber RE, et al. Amaurosis fugax and ocular infarction in adolescents and young adults. Ann Neurol 1989; 26:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/5\">",
"      Donders RC, Dutch TMB Study Group. Clinical features of transient monocular blindness and the likelihood of atherosclerotic lesions of the internal carotid artery. J Neurol Neurosurg Psychiatry 2001; 71:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/6\">",
"      Pessin MS, Duncan GW, Mohr JP, Poskanzer DC. Clinical and angiographic features of carotid transient ischemic attacks. N Engl J Med 1977; 296:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/7\">",
"      Marshall J, Meadows S. The natural history of amaurosis fugax. Brain 1968; 91:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/8\">",
"      Burde RM. Amaurosis fugax. An overview. J Clin Neuroophthalmol 1989; 9:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/9\">",
"      Richard, KT, Chan, L, Fleming, JF, et al, for the NASCET Group, London, Ontario Canada. Neurology 1996; 46:A392.",
"     </a>",
"    </li>",
"    <li>",
"     Hoyt WF. Ocular symptoms and signs. In: Extracranial Occlusive Cerebrovascular Disease Diagnosis and Management, Wylie EJ, Ehrenfeld W.  (Eds), WB Saunders, Philadelphia 1970. p.64.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/11\">",
"      Lord RS. Transient monocular blindness. Aust N Z J Ophthalmol 1990; 18:299.",
"     </a>",
"    </li>",
"    <li>",
"     Newman NJ. Cerebrovascular disease. In: Walsh and Hoyt's Clinical Neuro-ophthalmology, 5th, Miller NR, Newman NJ.  (Eds), Lippincott, Williams &amp; Wilkins, Baltimore 1998. p.3323.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/13\">",
"      Fisher CM. Late-life migraine accompaniments as a cause of unexplained transient ischemic attacks. Can J Neurol Sci 1980; 7:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/14\">",
"      Kosmorsky GS, Rosenfeld SI, Burde RM. Transient monocular obscuration--?amaurosis fugax: a case report. Br J Ophthalmol 1985; 69:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/15\">",
"      Russell RW, Page NG. Critical perfusion of brain and retina. Brain 1983; 106 (Pt 2):419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/16\">",
"      Kaiboriboon K, Piriyawat P, Selhorst JB. Light-induced amaurosis fugax. Am J Ophthalmol 2001; 131:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/17\">",
"      Furlan AJ, Whisnant JP, Kearns TP. Unilateral visual loss in bright light. An unusual symptom of carotid artery occlusive disease. Arch Neurol 1979; 36:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/18\">",
"      Galetta SL, Balcer LJ, Liu GT. Giant cell arteritis with unusual flow-related neuro-ophthalmologic manifestations. Neurology 1997; 49:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/19\">",
"      Levin LA, Mootha VV. Postprandial transient visual loss. A symptom of critical carotid stenosis. Ophthalmology 1997; 104:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/20\">",
"      Knapp ME, Flaharty PM, Sergott RC, et al. Gaze-induced amaurosis from central retinal artery compression. Ophthalmology 1992; 99:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/21\">",
"      Jehn A, Frank Dettwiler B, Fleischhauer J, et al. Exercise-induced vasospastic amaurosis fugax. Arch Ophthalmol 2002; 120:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/22\">",
"      Imes RK, Hoyt WF. Exercise-induced transient visual events in young healthy adults. J Clin Neuroophthalmol 1989; 9:178.",
"     </a>",
"    </li>",
"    <li>",
"     Miller, NR. Embolic causes of transient monocular visual loss: Appearance, source, and assessment. In: Ophthalmology Clinics of North America, Katz, B (Ed), W.B. Saunders, Philadelphia 1996. p.359.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/24\">",
"      Cugati S, Wang JJ, Rochtchina E, Mitchell P. Ten-year incidence of retinal emboli in an older population. Stroke 2006; 37:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/25\">",
"      Wang JJ, Cugati S, Knudtson MD, et al. Retinal arteriolar emboli and long-term mortality: pooled data analysis from two older populations. Stroke 2006; 37:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/26\">",
"      Current management of amaurosis fugax. The Amaurosis Fugax Study Group. Stroke 1990; 21:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/27\">",
"      Anderson DC, Kappelle LJ, Eliasziw M, et al. Occurrence of hemispheric and retinal ischemia in atrial fibrillation compared with carotid stenosis. Stroke 2002; 33:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/28\">",
"      Mead GE, Lewis SC, Wardlaw JM, Dennis MS. Comparison of risk factors in patients with transient and prolonged eye and brain ischemic syndromes. Stroke 2002; 33:2383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/29\">",
"      Hurwitz BJ, Heyman A, Wilkinson WE, et al. Comparison of amaurosis fugax and transient cerebral ischemia: a prospective clinical and arteriographic study. Ann Neurol 1985; 18:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/30\">",
"      Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1991; 325:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/31\">",
"      Bruno A, Corbett JJ, Biller J, et al. Transient monocular visual loss patterns and associated vascular abnormalities. Stroke 1990; 21:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/32\">",
"      Wilterdink JL, Easton JD. Vascular event rates in patients with atherosclerotic cerebrovascular disease. Arch Neurol 1992; 49:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/33\">",
"      De Schryver EL, Algra A, Donders RC, et al. Type of stroke after transient monocular blindness or retinal infarction of presumed arterial origin. J Neurol Neurosurg Psychiatry 2006; 77:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/34\">",
"      Benavente O, Eliasziw M, Streifler JY, et al. Prognosis after transient monocular blindness associated with carotid-artery stenosis. N Engl J Med 2001; 345:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/35\">",
"      Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol 1998; 125:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/36\">",
"      Hayreh SS, Podhajsky PA, Zimmerman B. Occult giant cell arteritis: ocular manifestations. Am J Ophthalmol 1998; 125:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/37\">",
"      Caselli RJ, Hunder GG, Whisnant JP. Neurologic disease in biopsy-proven giant cell (temporal) arteritis. Neurology 1988; 38:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/38\">",
"      Wells M, Foroozan R. Transient visual loss may anticipate occipital infarction from hemodialysis. Am J Kidney Dis 2004; 43:e29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/39\">",
"      Luchi M, Warren KA, Saberhagen C, Hinthorn D. Transient visual loss due to severe anemia in a patient with AIDS. J La State Med Soc 1999; 151:82.",
"     </a>",
"    </li>",
"    <li>",
"     Biousse, V. Cerebrovascular disease. In: Walsh and Hoyt's Clinical Neuro-ophthalmology, Vol 2, 6th ed, Miller, NR, Newman, NJ, Biousse, V, Kerrison, JB (Eds), Williams and Wilkins, Baltimore 2005. p.1967.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/41\">",
"      Tatemichi TK, Chamorro A, Petty GW, et al. Hemodynamic role of ophthalmic artery collateral in internal carotid artery occlusion. Neurology 1990; 40:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/42\">",
"      Mimura T, Funatsu H, Kitano S, et al. Diabetic retinopathy with repeated amaurosis fugax caused by orthostatic hypotension. Am J Ophthalmol 2003; 136:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/43\">",
"      Schlingemann RO, Smit AA, Lunel HF, Hijdra A. Amaurosis fugax on standing and angle-closure glaucoma with clomipramine. Lancet 1996; 347:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/44\">",
"      Asherson RA, Cervera R. Unusual manifestations of the antiphospholipid syndrome. Clin Rev Allergy Immunol 2003; 25:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/45\">",
"      Digre KB, Durcan FJ, Branch DW, et al. Amaurosis fugax associated with antiphospholipid antibodies. Ann Neurol 1989; 25:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/46\">",
"      Glueck CJ, Goldenberg N, Bell H, et al. Amaurosis fugax: associations with heritable thrombophilia. Clin Appl Thromb Hemost 2005; 11:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/47\">",
"      Fry CL, Carter JE, Kanter MC, et al. Anterior ischemic optic neuropathy is not associated with carotid artery atherosclerosis. Stroke 1993; 24:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/48\">",
"      Terao S, Takeda A, Miura N, et al. Clinical and pathophysiological features of amaurosis fugax in Japanese stroke patients. Intern Med 2000; 39:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/49\">",
"      Cackett P, Weir C. Wegener's granulomatosis presenting with amaurosis fugax. Eye (Lond) 2002; 16:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/50\">",
"      Libman RB, Masters SR, de Paola A, Mohr JP. Transient monocular blindness associated with cocaine abuse. Neurology 1993; 43:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/51\">",
"      Ubogu E. Amaurosis fugax associated with phencyclidine inhalation. Eur Neurol 2001; 46:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/52\">",
"      Pece A, Patelli F, Milani P, Pierro L. Transient visual loss after amyl Isobutyl nitrite abuse. Semin Ophthalmol 2004; 19:105.",
"     </a>",
"    </li>",
"    <li>",
"     Hayreh, SS. Central retinal vein occlusion. In: The Eye and Systemic Disease, Edition 2, Mausolf, FA (Ed), CV Mosby, St. Louis 1980. p.223.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/54\">",
"      Shuler RK Jr, Biousse V, Newman NJ. Transient monocular visual loss in two patients with impending central retinal vein occlusion. J Neuroophthalmol 2005; 25:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/55\">",
"      Prisco D, Marcucci R. Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach. Pathophysiol Haemost Thromb 2002; 32:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/56\">",
"      Biousse V, Newman NJ, Sternberg P Jr. Retinal vein occlusion and transient monocular visual loss associated with hyperhomocystinemia. Am J Ophthalmol 1997; 124:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/57\">",
"      Cugati S, Wang JJ, Knudtson MD, et al. Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts. Ophthalmology 2007; 114:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/58\">",
"      O'Sullivan F, Rossor M, Elston JS. Amaurosis fugax in young people. Br J Ophthalmol 1992; 76:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/59\">",
"      Slavin ML. Amaurosis fugax in the young. Surv Ophthalmol 1997; 41:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/60\">",
"      Burger SK, Saul RF, Selhorst JB, Thurston SE. Transient monocular blindness caused by vasospasm. N Engl J Med 1991; 325:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/61\">",
"      Winterkorn JM, Teman AJ. Recurrent attacks of amaurosis fugax treated with calcium channel blocker. Ann Neurol 1991; 30:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/62\">",
"      Heckmann JG, Gaul C, Neund&ouml;rfer B, et al. Vasospastic amaurosis fugax. J Neurol Neurosurg Psychiatry 2003; 74:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/63\">",
"      Bernard GA, Bennett JL. Vasospastic amaurosis fugax. Arch Ophthalmol 1999; 117:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/64\">",
"      The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24suppl1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/65\">",
"      Winterkorn JM, Kupersmith MJ, Wirtschafter JD, Forman S. Brief report: treatment of vasospastic amaurosis fugax with calcium-channel blockers. N Engl J Med 1993; 329:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/66\">",
"      Flammer J, Pache M, Resink T. Vasospasm, its role in the pathogenesis of diseases with particular reference to the eye. Prog Retin Eye Res 2001; 20:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/67\">",
"      Smith KJ, McDonald WI. The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans R Soc Lond B Biol Sci 1999; 354:1649.",
"     </a>",
"    </li>",
"    <li>",
"     Beck, RW. Optic Neuritis. In: Walsh and Hoyt's Clinical Neuro-ophthalmology, 5th Ed, Miller, NR, Newman, NJ (Eds), Lippencott, Williams &amp; Wilkins, Baltimore 1998. p.599.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/69\">",
"      Lepore FE. Uhthoff's symptom in disorders of the anterior visual pathways. Neurology 1994; 44:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/70\">",
"      Sadun AA, Currie JN, Lessell S. Transient visual obscurations with elevated optic discs. Ann Neurol 1984; 16:489.",
"     </a>",
"    </li>",
"    <li>",
"     Miller, NR. Papilledema. In: Walsh and Hoyt's Clinical Neuro-ophthalmology, 5th Ed, Miller, NR, Newman, NJ (Eds), Lippencott, Williams &amp; Wilkins Baltimore 1998. p.487.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/72\">",
"      Otto CS, Coppit GL, Mazzoli RA, et al. Gaze-evoked amaurosis: a report of five cases. Ophthalmology 2003; 110:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/73\">",
"      Khan MA, Dhillon B. Epiphora due to Kaposi's sarcoma of the nasolacrimal duct. Br J Ophthalmol 1999; 83:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/74\">",
"      Ravits J, Seybold ME. Transient monocular visual loss from narrow-angle glaucoma. Arch Neurol 1984; 41:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/75\">",
"      Cates CA, Newman DK. Transient monocular visual loss due to uveitis-glaucoma-hyphaema (UGH) syndrome. J Neurol Neurosurg Psychiatry 1998; 65:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/76\">",
"      Hsu HY, Chao AC, Chen YY, et al. Reflux of jugular and retrobulbar venous flow in transient monocular blindness. Ann Neurol 2008; 63:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/77\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/78\">",
"      Leao, AA. Spreading depression of activity in the cerebral cortex. J Neurophysiol 1944; 7:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/79\">",
"      Russell MB, Olesen J. A nosographic analysis of the migraine aura in a general population. Brain 1996; 119 ( Pt 2):355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/80\">",
"      Wijman CA, Wolf PA, Kase CS, et al. Migrainous visual accompaniments are not rare in late life: the Framingham Study. Stroke 1998; 29:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/81\">",
"      Bien CG, Benninger FO, Urbach H, et al. Localizing value of epileptic visual auras. Brain 2000; 123 ( Pt 2):244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/82\">",
"      Sadeh M, Goldhammer Y, Kuritsky A. Postictal blindness in adults. J Neurol Neurosurg Psychiatry 1983; 46:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/83\">",
"      Barry E, Sussman NM, Bosley TM, Harner RN. Ictal blindness and status epilepticus amauroticus. Epilepsia 1985; 26:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/84\">",
"      Pessin MS, Kwan ES, DeWitt LD, et al. Posterior cerebral artery stenosis. Ann Neurol 1987; 21:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/85\">",
"      Tierney MC, Reid DW, Zorzitto ML, et al. The differential diagnosis of Alzheimer's disease: conceptual and methodological issues. Can J Neurol Sci 1986; 13:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/86\">",
"      Biousse V, Touboul PJ, D'Anglejan-Chatillon J, et al. Ophthalmologic manifestations of internal carotid artery dissection. Am J Ophthalmol 1998; 126:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/87\">",
"      Caplan LR, Wityk RJ, Glass TA, et al. New England Medical Center Posterior Circulation registry. Ann Neurol 2004; 56:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/88\">",
"      Belden JR, Caplan LR, Pessin MS, Kwan E. Mechanisms and clinical features of posterior border-zone infarcts. Neurology 1999; 53:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/89\">",
"      Kramer M, Goldenberg-Cohen N, Shapira Y, et al. Role of transesophageal echocardiography in the evaluation of patients with retinal artery occlusion. Ophthalmology 2001; 108:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/90\">",
"      Kline, LB. The natural history of patients with amaurosis fugax. Ophthal Clin North Am 1996; 9:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/26/10666/abstract/91\">",
"      Newman, NJ. Evaluating the patient with transient monocular vision loss: the young vs the elderly. Ophthalmol Clin North Am 1996; 9:455.",
"     </a>",
"    </li>",
"    <li>",
"     Biousse, V. Cerebrovascular disease. In: Walsh and Hoyt's Clinical Neuro-ophthalmology, Vol 2, 6th ed, Miller NR, Newman NJ, Biousse V, Kerrison JB (Eds), Williams and Wilkins, Baltimore 2005. p.1967.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5245 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C7EAEF3114-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_26_10666=[""].join("\n");
var outline_f10_26_10666=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      APPROACH TO TRANSIENT VISUAL LOSS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Historical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Monocular versus binocular",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Description of visual symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Precipitating factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Associated symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Medical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CAUSES OF TRANSIENT MONOCULAR VISUAL LOSS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Ischemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Carotid artery disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Giant cell arteritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Other ischemic etiologies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Retinal vein occlusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Retinal vasospasm and retinal migraine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Optic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Papilledema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Optic nerve compression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Ocular causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Idiopathic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      CAUSES OF TRANSIENT BINOCULAR VISUAL LOSS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Migraine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Seizure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Vertebrobasilar ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      DIAGNOSTIC EVALUATION OF TRANSIENT VISUAL LOSS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Young patients without risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5245\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5245|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/33/39454\" title=\"picture 1\">",
"      Retinal ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/3/23601\" title=\"picture 2\">",
"      Hollenhorst plaque retinal artery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5245|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/24/24972\" title=\"table 1\">",
"      Causes of TVL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/26/39339\" title=\"table 2\">",
"      Diagnostic tests TVL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/36/42569?source=related_link\">",
"      Approach to the patient with visual hallucinations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3882?source=related_link\">",
"      Central and branch retinal artery occlusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32458?source=related_link\">",
"      Epidemiology and clinical features of multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9208?source=related_link\">",
"      Etiology and classification of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31033?source=related_link\">",
"      Evaluation of carotid artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17417?source=related_link\">",
"      Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/1/23578?source=related_link\">",
"      Localization-related (partial) epilepsy: Causes and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21530?source=related_link\">",
"      Management of symptomatic carotid atherosclerotic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/58/27558?source=related_link\">",
"      Nonarteritic anterior ischemic optic neuropathy: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30552?source=related_link\">",
"      Overview and differential diagnosis of papilledema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=related_link\">",
"      Overview of the evaluation of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39273?source=related_link\">",
"      Posterior circulation cerebrovascular syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34217?source=related_link\">",
"      Treatment of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_26_10667="Titratable acid and pH";
var content_f10_26_10667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F70080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F70080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    pH dependence of titratable acid excretion",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Segment",
"      </td>",
"      <td class=\"subtitle1\">",
"       pH",
"      </td>",
"      <td class=\"subtitle1\">",
"       HPO4(2-), mmol",
"      </td>",
"      <td class=\"subtitle1\">",
"       HPO4-, mmol",
"      </td>",
"      <td class=\"subtitle1\">",
"       Amount buffered by HPO4(2-), mmol",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Filtrate",
"      </td>",
"      <td>",
"       7.40",
"      </td>",
"      <td>",
"       40",
"      </td>",
"      <td>",
"       10",
"      </td>",
"      <td>",
"       0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Proximal tubule",
"      </td>",
"      <td>",
"       6.80",
"      </td>",
"      <td>",
"       25",
"      </td>",
"      <td>",
"       25",
"      </td>",
"      <td>",
"       15",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Final urine",
"      </td>",
"      <td>",
"       4.80",
"      </td>",
"      <td>",
"       0.5",
"      </td>",
"      <td>",
"       49.5",
"      </td>",
"      <td>",
"       39.5",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of tubular fluid pH on the degree of buffering by phosphate [HPO4(2-)] if 50 mmol of phosphate is excreted.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_26_10667=[""].join("\n");
var outline_f10_26_10667=null;
var title_f10_26_10668="Etiology fourth nerve palsy";
var content_f10_26_10668=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80378&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiology of fourth nerve palsy in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Midbrain (nuclear/fascicular)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aplasia of the nucleus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vascular lesions (eg, brainstem arteriovenous malformations)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Demyelination (multiple sclerosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brainstem hemorrhage, ischemia, or infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trauma (including surgical)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neoplasm (eg, glioma, metastasis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Subarachnoid space",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aneurysms (eg, superior cerebellar artery)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased intracranial pressure and hydrocephalus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infections (eg, mastoiditis, encephalitis meningitis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postlumbar puncture or spinal anesthesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neoplasm (eg, carcinomatous meningitis, cerebellar hemangioblastoma, ependymoma, meningioma, metastasis, neurilemmoma, pineal tumors, or trochlear nerve sheath tumors)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cavernous sinus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neoplasm (eg, meningioma, metastasis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infection (eg, syphilis, tuberculosis, herpes zoster)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammation (eg, sarcoid, granulomatosis with polyangiitis (Wegener's), or the Tolosa-Hunt syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vascular lesions (eg, carotid-cavernous fistulas, internal carotid artery aneurysm)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Orbital",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neoplasm (eg, hemangioma, metastasis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infection (orbital cellulitis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infiltration (eg, sarcoid)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammation (eg, orbital inflammatory pseudotumor)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trauma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_26_10668=[""].join("\n");
var outline_f10_26_10668=null;
var title_f10_26_10669="Hyperfract RT Diff pont glioma";
var content_f10_26_10669=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F59706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F59706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hyperfractionated radiation therapy for diffuse pontine gliomas",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Protocol [references]",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        Dose per fx/total dose",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        TTP (mos)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        MST (mos)",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Survival&nbsp;(percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        1yr",
"       </td>",
"       <td class=\"subtitle2\">",
"        2 yr",
"       </td>",
"       <td class=\"subtitle2\">",
"        3 yr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        POG* [1, 2, 3]",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        1.1 Gy/66 Gy",
"       </td>",
"       <td>",
"        6.5",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        1.17 Gy/70.2 Gy",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        1.26 Gy/75.6 Gy",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        CHOP/NYU [4]",
"       </td>",
"       <td>",
"        16&nbsp;",
"       </td>",
"       <td>",
"        1.2 Gy/64.8 Gy",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        1 Gy/72 Gy",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        CCG [5, 6, 7]",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        1 Gy/72 Gy",
"       </td>",
"       <td>",
"        5.5",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        66",
"       </td>",
"       <td>",
"        1 Gy/78 Gy",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        9.5",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        UCSF [8, 9]",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        1 Gy/72Gy",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        1 Gy/78 Gy",
"       </td>",
"       <td>",
"        8.4",
"       </td>",
"       <td>",
"        10.8",
"       </td>",
"       <td>",
"       </td>",
"       <td>",
"       </td>",
"       <td>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TTP: time to progression; MST: median survival time; POG: Pediatric Oncology Group; CHOP: Children's Hospital of Philadelphia; NYU: New York University; CCG: Childrens Cancer Group; UCSF: University of California, San Francisco.",
"    </div>",
"    <div class=\"reference\">",
"     1. Freeman, CR, et al. IJROBP 1988; 15:311.",
"     <br>",
"      2. Freeman, CR, et al. Cancer 1991; 68:474.",
"      <br>",
"       3. Freeman, CR, et al. IJROBP 1993; 27:197.",
"       <br>",
"        4. Packer, RJ, et al. IJROBP 1987; 13:1647.",
"        <br>",
"         5. Packer, RJ, et al. Ann Neurol 1990; 27:167.",
"         <br>",
"          6. Packer, RJ, et al. Cancer 1994; 74:1827. 7. Packer, RJ, et al. Cancer 1993; 72:1414.",
"          <br>",
"           8. Edwards, MS, et al. J Neurosurg 1989; 70:691.",
"           <br>",
"            9. Prados, MD, et al. IJROBP1995; 32:85.",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_26_10669=[""].join("\n");
var outline_f10_26_10669=null;
var title_f10_26_10670="Contents: Spinal disease and back pain";
var content_f10_26_10670=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?23/51/24382\">",
"       Adult Primary Care and Internal Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Spinal disease and back pain",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Spinal disease and back pain",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Ankylosing spondylitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/23/35194\">",
"           Assessment and treatment of ankylosing spondylitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/9/151\">",
"           Clinical manifestations of ankylosing spondylitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/51/12090\">",
"           Pathogenesis of spondyloarthritis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Low back pain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/10/18601\">",
"           Approach to the diagnosis and evaluation of low back pain in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/7/14458\">",
"           Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fractures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/21/12633\">",
"           Diagnostic testing for low back pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/43/6841\">",
"           Exercise-based therapy for low back pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/28/1480\">",
"           Lumbar spinal stenosis: Pathophysiology, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/15/22776\">",
"           Lumbar spinal stenosis: Treatment and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/34/42535\">",
"           Occupational low back pain: Evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/47/14072\">",
"           Occupational low back pain: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/16/41222\">",
"           Spinal manipulation in the treatment of musculoskeletal pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/52/39753\">",
"           Subacute and chronic low back pain: Nonsurgical interventional treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/24/19850\">",
"           Subacute and chronic low back pain: Pharmacologic and noninterventional treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/5/34905\">",
"           Subacute and chronic low back pain: Surgical treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/21/13658\">",
"           Treatment of acute low back pain",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neck pain",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/18/27944\">",
"           Cervical spondylotic myelopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/19/36152\">",
"           Clinical features and diagnosis of cervical radiculopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/24/1418\">",
"           Evaluation of the patient with neck pain and cervical spine disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/47/17144\">",
"           Treatment of cervical radiculopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/36/23113\">",
"           Treatment of neck pain",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/6/35940\">",
"           Coccydynia (coccygodynia)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/16/41222\">",
"           Spinal manipulation in the treatment of musculoskeletal pain",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-3B43DF60E7-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f10_26_10670=[""].join("\n");
var outline_f10_26_10670=null;
var title_f10_26_10671="Hormones gonadotroph adenoma";
var content_f10_26_10671=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F52535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F52535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hormone levels in men with a gonadotroph adenoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 171px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Basal serum concentrations of follicle stimulating hormone (FSH), luteinizing hormone (LH), free alpha subunit, and LH&beta; subunit in 38 men with clinically nonfunctioning gonadotroph macroadenomas. Each dot represents the value in a single patient; the horizontal lines encompass the ranges of an age-matched control group. Seventeen men had supranormal levels of at least one intact hormone or subunit, and four had multiple basal elevations.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Daneshdoost L, Gennarelli TA, Bashey HM, et al. Identification of gonadotroph adenomas in men with clinically nonfunctioning adenomas by the luteinizing hormone beta subunit response to thyrotropin-releasing hormone.&nbsp;J Clin Endocrinol Metab 1993; 77:1352.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_26_10671=[""].join("\n");
var outline_f10_26_10671=null;
